

Numerical Methods for the Design and Description of In Vitro Expansion Processes of Human Mesenchymal Stem Cells

4
5
6
7

Valentin Jossen, Dieter Eibl, and Regine Eibl

8
9

Contents

10

1	Introduction	11
2	In Vitro Expansion Approaches: Current Situation	12
2.1	Planar Approach (2D Cultures)	13
2.2	Dynamic Approach (3D Cultures)	14
3	Computational Fluid Dynamics as a Modern Tool for Bioreactor Characterization	15
3.1	Modelling Approaches	16
3.2	Advanced Fluid Flow Characterization of Small-Scale Spinner Flasks: A Case Study	17
4	Mathematical Growth Modelling of MC-Based hMSC Expansions	18
4.1	Modelling Approaches	19
4.2	Kinetic Growth Model for the MC-Based hMSC Expansion: A Case Study	20
5	Conclusions and Outlook	21
	References	22


Abstract Human mesenchymal stem cells (hMSCs) are a valuable source of cells 23
for clinical applications (e.g., treatment of acute myocardial infarction or inflamma- 24
tory diseases), especially in the field of regenerative medicine. However, for autolo- 25
gous (patient-specific) and allogeneic (off-the-shelf) hMSC-based therapies, 26
in vitro expansion is necessary prior to the clinical application in order to achieve 27
the required cell numbers. Safe, reproducible, and economic in vitro expansion of 28
hMSCs for autologous and allogeneic therapies can be problematic because the cell 29
material is restricted and the cells are sensitive to environmental changes. It is 30
beneficial to collect detailed information on the hydrodynamic conditions and cell 31

V. Jossen (✉), D. Eibl, and R. Eibl
Zurich University of Applied Sciences – Institute of Chemistry and Biotechnology, Wädenswil,
Switzerland
e-mail: valentin.jossen@zhaw.ch

32 growth behavior in a bioreactor system, in order to develop a so called “Digital
 33 Twin” of the cultivation system and expansion process. Numerical methods, such as
 34 computational fluid dynamics (CFD) which has become widely used in the biotech
 35 industry for studying local characteristics within bioreactors or kinetic growth
 36 modelling, provide possible solutions for such tasks.

37 In this review, we will present the current state-of-the-art for the in vitro expansion
 38 of hMSCs. Different numerical tools, including numerical fluid flow simulations
 39 and cell growth modelling approaches for hMSCs, will be presented. In
 40 addition, a case study demonstrating the applicability of CFD and kinetic growth
 41 modelling for the development of an MC-based hMSC process will be shown.

42 Graphical Abstract



Keywords Computational fluid dynamics, Euler-Euler model, Euler-Lagrange
 43 model, Human mesenchymal stem cells, Kinetic growth modelling, Microcarrier
 44 technology, Single-use bioreactor

46 Abbreviations

48	CC	Collagen-coated
49	CFD	Computational fluid dynamics
50	DMEM	Dulbecco's Modified Eagle Medium
51	DSP	Downstream processing
52	ECM	Extracellular matrix

bFGF	Basic fibroblast growth factor	53
FBS	Fetal bovine serum	54
GMP	Good manufacturing practice	55
hASC	Human adipose tissue-derived stromal/stem cells	56
hBM-MSc	Human bone marrow-derived mesenchymal stem cells	57
hMSCs	Human mesenchymal stem cells	58
hPL	Human platelet lysate	59
HGF	Hepatocyte growth factor	60
HSB	Hemispherical-bottom bioreactor	61
LDA	Laser Doppler anemometry	62
LES	Large eddy simulation	63
α MEM	Modified Eagle Medium	64
MC	Microcarrier	65
MCB	Master cell bank	66
MRF	Moving reference frame	67
OTR	Oxygen transfer rate	68
PIV	Particle image velocimetry	69
PS	Polystyrene-based	70
RB	Round-bottom bioreactor	71
RMSD	Root mean square deviation	72
SIMPLE	Semi-implicit method for pressure-linked equations	73
SM	Sliding mesh	74
SU	Single use	75
UCM	Umbilical cord-derived mesenchymal stem cells	76
USP	Upstream processing	77
VEGF	Vascular endothelial growth factor	78
VOF	Volume of fluid	79
WCB	Working cell bank	80
Latin Symbols		81
Amn (mmol/L)	Ammonium concentration	82
D_{O_2} (m^2/s)	Oxygen diffusivity	83
D_R (m)	Vessel diameter	84
EF	Expansion factor	85
F (N)	Force	86
Glc (mmol/L)	Glucose concentration	87
h/H_L	Geometrical ratio between a certain height and the liquid height	88
h_R/D_R	Geometrical ratio between impeller installation height and the vessel diameter (= off-bottom clearance)	89
H_L (m)	Liquid height	90
H_L/D	Geometrical ratio between liquid height and vessel diameter	91

92	k_{at} (d^{-1})	Cell attachment constant
93	k_{det} (d^{-1})	Cell detachment constant
94	K_{Amm} (mmol/L)	Inhibition constant of ammonium
95	K_{Glc} (mmol/L)	Monod constant of glucose
96	K_{Lac} (mmol/L)	Inhibition constant of lactate
97	Lac (mmol/L)	Lactate concentration
98	N (rpm)	Impeller speed
99	N_{sLu} (rpm)	Lower limit of N_{sI} suspension criterion
100	N_{sI} (rpm)	1s or just suspended criterion
101	PDL	Population doubling level
102	P/V (W/m^3)	Specific (volumetric) power input
103	p_{Amm} (mmol/cell/d)	Specific ammonium production rate (growth-independent)
104	p_{Lac} (mmol/cell/d)	Specific lactate production rate (growth-independent)
105	q_{Amm} (mmol/cell/d)	Specific ammonium production rate (growth-dependent)
106	q_{Glc} (mmol/cell/d)	Specific glucose consumption rate
107	q_{Lac} (mmol/cell/d)	Specific lactate production rate (growth-dependent)
108	Re	Reynolds number
109	r/R	Dimensionless radial coordinates
110	t_c (s)	Contact time
111	t_{cir} (s)	Particle circulation times
112	t_d (d)	Doubling time of cell population
113	t_l (d)	Lag or cell adaption time
114	t_{res} (s)	Particle residence time
115	u_{tip} (m/s)	Impeller tip speed
116	\vec{u} (m/s)	Velocity vector in x-direction
117	V_{min} (mL)	Minimal working volume
118	V_{max} (mL)	Maximum working volume
119	\vec{v} (m/s)	Velocity vector in y-direction
120	\vec{w} (m/s)	Velocity vector in z-direction
121	X_A (cells/cm ²)	Cell concentration on surface
122	X_{max} (cells/cm ²)	Maximum cell concentration on surface
123	X_{Sus} (cells/mL)	Cell concentration in suspension
124	X_V (cells/cm ²)	Cell concentration of viable cells ($X_{Sus} + X_A$)
125	$Y_{Lac/Glc}$ (mmol/mmol)	Lactate yield per glucose equivalent
126	Y_{X/O_2} (1/mmol)	Yield coefficient/cells per mmol oxygen

127 Greek Symbols

128	α	Cell adaption phase coefficient
129	α_{MC}	MC volume fraction
130	δ_{Glc}	Step response in glucose balance to avoid negative glucose values ($\delta_{Glc} = 0$ or 1)
131	η_L (Pa s)	Dynamic viscosity of the liquid

π	Mathematical constant (≈ 3.1415)	132
ρ_L (kg/m ³)	Density of the liquid	133
τ_{nn} (Pa)	Local normal stress	134
τ_{nt} (Pa)	Local shear stress	135
μ (1/d)	Specific growth rate	136
μ_{max} (1/d)	Maximum specific growth rate	137

1 Introduction 138

The successful development and application of cell-based therapies have the potential to treat a number of currently incurable diseases and to improve patient care. It is therefore not surprising that cell-based therapies have become increasingly important in the field of regenerative medicine, as the expected revenue for 2020 of up to US\$ 6.09 billion indicates [1]. Special attention in the field of regenerative medicine is currently being paid to human mesenchymal stem cells (hMSCs). This is unsurprising due to their existence in postnatal tissues (e.g., adipose tissue, bone marrow, the umbilical cord), their high proliferation potential, and their immunosuppressive, immunoregulating, migrating, and trophic properties and low ethical concerns. At the beginning of 2020, 41 clinical trials involving hMSCs were registered (www.clinicaltrials.gov). In addition to the large number of currently ongoing clinical studies, 17 hMSC-based products have received marketing authorization to date (see Table 1), demonstrating the need for reproducible and robust cell processing methods. Product manufacturing takes place mainly with mesenchymal stem cells derived from human bone marrow (hBM-MSC; 11 products), followed by adipose tissue-derived stem cells (hASCs; 5 products).

In general, hMSC-based therapies can be broadly divided into two categories: patient-specific therapies (autologous) and off-the-shelf therapies (allogeneic). From an economic point of view, the allogeneic therapy approach seems to be the most attractive option at present [2, 3]. However, independent of the therapy approach, an in vitro expansion of hMSCs is required to deliver an effective therapeutic dose (1–5 million hMSCs/kg body weight [4–6]). The intention of the in vitro expansion step is to manufacture a sufficient number of hMSCs under good manufacturing practice (GMP) conditions and in a cost-effective manner. It is clear that in vitro manufacturing of hMSCs is often difficult because the cells, which are the product, are directly isolated from body tissue and are genetically unstable in vitro (e.g., cellular senescence) [7]. In addition, significant differences in the cell yield, the proliferation rate, and the differentiation potential have been found between different donors, as well as for different ages of donor and health conditions [8–10]. Apart from the biological variability of the cell material, hMSCs are also sensitive to environmental changes and chemical and physical stresses [11, 12]. As a result, all these aspects place high demands on the in vitro cell expansion process. MSC manufacturing is characterized

t1.1 **Table 1** Available hMSC-based products (as of May 2020)

t1.2	Medicinal product	Company	Therapy/cell type	Indication	Market
t1.3	Allostem	AlloSource	Allogeneic ASC	Bone regeneration	USA
t1.4	Alofisel	TiGenix-Takeda	Allogeneic ASC	Anal fistula in Crohn's disease	EU
t1.5	AstroStem	Biostar	Autologous ASC	Alzheimer's disease	Japan
t1.6	aJointStem	Biostar	Autologous ASC	Degenerative arthritis	Japan
t1.7	Cartistem	Medipost	Allogeneic UCM	Degenerative arthritis	Korea
t1.8	Cupistem	Anterogen	Allogeneic ASC	Anal fistula in Crohn's disease	Korea
t1.9	Grafix	Osiris Therapeutics	Allogeneic BM-MSC	Soft tissue defects	USA
t1.10	HearticellGram-AMI	FCB PharmiCell	Autologous BM-MSC	Acute myocardial infarction	Korea
t1.11	Neuronata-R	Corestem	Allogeneic BM-MSC	Amyotrophic lateral sclerosis	Korea
t1.12	OsteoCel	NuVasive	Allogeneic BM-MSC	Spinal bone regeneration	USA
t1.13	OvationOS	Osiris Therapeutics	Allogeneic BM-MSC	Bone regeneration	USA
t1.14	Prochymal	Osiris Therapeutics	Allogeneic BM-MSC	Acute graft vs. host disease	Canada
t1.15	Stemirac	NIPRO Corp	Autologous BM-MSC	Spinal cord injury	Japan
t1.16	Stempeucel	Stempeutics	Allogeneic BM-MSC	Critical limb ischemia	India
t1.17	TemCell	JCR Pharm.	Allogeneic BM-MSC	Acute graft vs. Host disease	Japan
t1.18	Trinity Elite	Orthofix	Allogeneic BM-MSC	Bone regeneration	USA
t1.19	Trinity Evolution	Orthofix	Allogeneic BM-MSC	Bone regeneration	USA

171 by different manufacturing steps covering upstream processing (USP), downstream
172 processing (DSP), formulation, and fill and finish operations. Typical USP operations
173 are the manufacturing of the Master Cell Bank (MCB) and Working Cell Bank
174 (WCB), seed cell production, and cell expansion at L-scale. DSP operations include
175 cell harvest, cell separation, washing as well as concentration procedures, and
176 medium exchange. Different economic studies have demonstrated that the USP,
177 and in particular the hMSC expansion, represents the main cost driver when exam-
178 ining the whole manufacturing process [3, 13, 14]. To reduce the number of
179 experiments and to increase the process knowledge during either the design and
180 development or the optimization phase, virtual representations of the hMSC pro-
181 duction process, so called "Digital Twins," are helpful. These virtual models allow
182 an approximation of real process conditions, a fact that is particularly important for

the production of cell therapeutics, as, among other things, cell material (in an autologous approach) may vary between batches. Process conditions must, therefore, be adapted to the biological starting material, increasing the complexity of the production process. Here application of a “Digital Twin,” which combines biochemical engineering data of the cultivation system with a mathematical model of the cell growth, is beneficial, as it tests different process conditions in silico and subsequently proposes optimal parameter combinations for the hMSC production process.

2 In Vitro Expansion Approaches: Current Situation

For the clinical application of hMSCs, the in vitro expansion of the cells represents an important step. Although recent studies have shown the difference in cell yield depending on the hMSC source (e.g., bone marrow vs. adipose tissue), the required therapeutic dose (1–5 million hMSCs/kg body weight) makes in vitro expansion mandatory independent on the hMSC-type. Therefore, different systems and cultivation strategies have been developed over the years for the expansion of hMSCs, which will be presented and discussed in the following sections.

2.1 Planar Approach (2D Cultures)

hMSCs are typically isolated by their capacity to adhere to plastic surfaces. Therefore, the simplest way to expand hMSCs is the usage of plastic vessels, such as T-flask or stacked plate systems, which allow for the expansion of the cells at laboratory and pilot plant production scale for early-phase clinical trials [15]. Planar expansion approaches in normal cell culture flasks (e.g., T-flasks) represent a cost-efficient and easy-to-operate solution. Maximum cell densities for hMSCs from the human bone marrow, the adipose tissue, and the umbilical cord have been reported in the literature in the range of 0.05 to 1.0×10^5 cells/cm² (PDL 2.8–7.4) for T-flask cultures performed with serum-containing and serum-free cell culture medium (see Table 2). Maximum cell densities for CellSTACK cultures were even reported in the range of 2.5 to 4.2×10^5 cells/cm² ($=1.59$ – 2.67×10^9 cells) using hMSCs from the bone marrow.

However, scale-up of such an hMSC expansion process would require a large number of cell culture flasks, which is by any means neither economic nor ecologic. Moreover, handling of multiple flasks in parallel is very labor and cost intensive (increased facility footprint) and may result in high flask-to-flask variabilities. In addition, the risk of contamination (e.g., bacteria, mycoplasma) is increased due to the large number of open manipulations. Alternatives to the normal cell culture flasks are stacked-plate or multi-tray culture systems, such as cell factories, which significantly increase the efficiency of the cultivation step by using several layers per cultivation system (up to 40-layer systems available). Thus, the absolute cell number

t2.1 **Table 2** Overview of hMSC expansions in different static, planar cultivation systems

t2.2	MSC type	2D cultivation system	Culture medium	Cell density	PDL	Ref.
t2.3	hBM-MSC	T-flasks (Greiner)	α MEM + 15 % FBS	$0.05\text{-}0.6 \times 10^5$ cells/cm ²	5.6 ± 1.8	[10]
t2.4		T-flask (CellBIND)	Corning stemgro hMSC	1.0×10^5 cells/cm ²	4-5	[16]
t2.5		CellSTACK-5	DMEM/ α MEM + hPL	$0.4\text{-}0.9 \times 10^5$ cells/cm ²	n/a	[6]
t2.6		CellSTACK-10	BD Mosaic SFM	2.5×10^5 cells/cm ²	n/a	[17]
t2.7		CellSTACK-10	DMEM + 10 % FBS	4.2×10^5 cells/cm ²	n/a	[17]
t2.8		Nunc Cell Factory-4	α MEM + 10 % FBS	1.8×10^5 cells/cm ²	4.9	[18]
t2.9	hASC	T-flasks (Corning)	UrSuppe SFM	0.7×10^5 cells/cm ²	2.8-3.2	[19]
t2.10	UCM	T-flask (Sarstedt)	DMEM + 10 % FCS	0.5×10^5 cells/cm ²	4.9	[20]
t2.11		CellSTACK-5	DMEM/ α MEM + hPL	$1.6\text{-}1.8 \times 10^5$ cells/cm ²	n/a	[6]




Fig. 1 Schematic representation of biochemical and physical parameters, which have an influence on planar hMSC cultures

220 per cultivation is significantly increased. Maximum cell densities have been reported
 221 in the literature in the range of 0.4 to 4.2×10^5 cells/cm² for hMSCs expanded in 5-
 222 and 10-layer multi-tray systems with serum-containing and serum-free cell culture
 223 medium (see Table 2). Due to the static nature of the multi-tray systems, there is
 224 always the risk of gradients in pH and pO₂ levels in the liquid phase, possibly
 225 introducing heterogeneities that affect cell growth and quality (see Fig. 1a, b).
 226 Moreover, the lack of sensors in the systems does not allow the maintenance of
 227 optimal set points for some physiochemical parameters (e.g., pH and pO₂), resulting
 228 in fluctuating conditions for the cells. The multi-tray systems are also not fully
 229 closed, meaning that open manipulations are routinely performed, which require
 230 clean room facilities and a class-A laminar flow hood for each manipulation.
 231 Interestingly, to date the main reviews on hMSC clinical trials specify that clinical
 232 grade cells have mainly been expanded in static 2D systems [6, 15, 21, 22]. However,
 233 in terms of GMP requirements, alternative procedures and cultivation systems, like

the spheroid- or microcarrier-based expansion in stirred SU bioreactors, are said to be the platforms for future cell therapeutic productions (see Sect. 2.2).

2.2 *Dynamic Approach (3D Cultures)*

As mentioned in Sect. 2.1, hMSCs are typically expanded under adherent conditions as a monolayer in 2D culture systems. However, isolation and growth of hMSCs on rigid tissue culture plastic have been described as promoting spreading of cells rich in actin-myosin stress fibers [23, 24]. Indeed, the static 2D culture systems represent an artificial environment which significantly differs from those of the MSC in vivo niche. Therefore, different efforts have been made over the years to establish dynamic 3D culture systems working with spheroids (see Sect. 2.2.1) or microcarriers (MCs, see Sect. 2.2.2). In dynamic bioreactor systems (stirred, wave-mixed, orbitally shaken, hollow fiber and fixed bed types), the culture medium is continuously agitated to provide a uniform environment, preventing the formation of physiochemical gradients and improving mass and heat transfer. Special attention is currently being paid to single-use (SU) versions, which significantly improve patient safety [25]. Even though different studies have recently shown the applicability of SU systems for MC-based hMSC production processes, challenges still exist.

For this reason, it makes sense to characterize the different bioreactor systems using appropriate process engineering and cell cultivation technique methods prior to usage or during process development, simultaneously assisting in the development of a “Digital Twin.” Several studies have been published that provide engineering parameters relating to mixing time, oxygen mass transfer, and power input for various SU bioreactor types. However, when considering the heterogeneous distribution of MCs, spheroids and hydrodynamics, and a detailed analysis of the fluid flow pattern, the MC distribution and the cell growth become worthwhile. Numerical methods, such as computational fluid dynamics (CFD) and kinetic growth models, are complementary methods to the experimental investigations and increase the process knowledge of hMSC production methods. Thus, numerical models can be used to support process development and scale-up.

2.2.1 *Growth in Spheroids*

hMSCs are often expanded in stirred SU bioreactors as self-assembling cell aggregates or spheroids that mimic the in situ conditions. Thus, compared to 2D monolayer cultures, 3D structures consisting of multiple cell-to-cell contact points are obtained. However, due to their heterogeneous nature, spheroids have been more successfully employed to study complex 3D cell structures and cell differentiation [26] than for hMSC mass expansion in stirred SU bioreactors, as indicated by the limited number of publications in this area (see Table 3).

t3.1 **Table 3** Bioreactors operated with spheroids

t3.2	MSC type	Bioreactor system	N	Medium	Seeding	D_{max}	Ref.
t3.3	hBM- MSC	100 mL Techne spinner	30 rpm	α MEM+15% FBS	0.2×10^5 cells/mL	135 μ m	[27]
t3.4		125 mL Shake flask	80 rpm	SFM medium	1×10^5 cells/mL	n/a	[28]
t3.5		125 mL Paddle bioreactor	80 rpm	PPRF-msc6	0.5×10^5 cells/mL	218 μ m	[29]
t3.6	hASC	100 mL BellCo spinner	70 rpm	α MEM+10% FBS	6×10^5 cells/mL	350 μ m	[30]

271 The main motivation for growing hMSCs as spheroids is to avoid the use of
 272 exogenous support materials, like scaffolds or MCs. Due to the absence of the
 273 exogenous support material, the cells are allowed to arrange themselves similar to
 274 living tissues [22, 31]. Cells self-assemble and interact under natural forces, permit-
 275 ting them to generate their own extracellular matrix (ECM), which serves as support
 276 for the cells to survive in suspension and to mimic the cell-to-cell and cell-to-matrix
 277 signaling networks [32, 33]. Investigations by Edmonson et al. [34] have shown that
 278 the cell morphology of hMSCs derived from spheroid cultures is comparable to
 279 those in bodily tissues. In addition, Caron et al. [35] have demonstrated that a stable
 280 hMSCs phenotype is retained in spheroid-based cultures, at least when only the
 281 minimum definition of an hMSC is considered [36, 37]. A study by Cheng et al. [38]
 282 highlighted that spheroid-derived hASCs exhibited lower cell senescence and a high
 283 secretion of angiogenic growth factors (e.g., HGF, VEGF), which was found to be
 284 beneficial for wound healing applications. Interestingly, several studies with
 285 hBM-MSCs have found that the 3D structure of the spheroids leads to higher yields
 286 of secreted immunomodulatory paracrine and anti-inflammatory factors (i.e., TSG-6,
 287 stanniocalcin-1, prostaglandin E2) [39, 40], although this was highly dependent on
 288 the cell culture medium formulation [41, 42]. The cell culture medium and its
 289 formulation play a critical role in spheroid-based hMSC expansions. For example,
 290 Zimmermann and McDevitt [41] found that hBM-MSCs expanded in serum-free cell
 291 culture medium displayed a reduced expression of prostaglandin E2, indoleamine
 292 2,3-dioxygenase, transforming growth factor- β 1, and interleukin-6 when compared
 293 with spheroids cultured in serum-containing cell culture medium. Since the cells are
 294 forced to aggregate to form spheroids, the medium must also contain adhesive
 295 molecules (e.g., laminins, integrins, E-cadherin, vitronectin) to facilitate cell-to-
 296 cell attachment [43]. However, for GMP-compliant hMSC productions, these
 297 recombinant human proteins represent a strong cost driver, which makes large-
 298 scale manufacturing expensive [44]. In addition to biochemical parameters, physical
 299 or process engineering parameters have a strong effect on the spheroid culture (see
 300 Fig. 2).

301 For example, oxygen tension has been shown to play a fundamental role in the
 302 spheroid formation. Spheroids generated in hypoxic conditions (2% O_2) produced
 303 higher amounts of ECM components (i.e., fibronectin, laminin, elastin) and higher




Fig. 2 Schematic representation of biochemical and physical parameters that have an influence on hMSC spheroid cultures

amounts of growth factors (i.e., VEGF, bFGF) [45]. Therefore, spheroids are 304 effective for the tuning of specific cell features but limited in terms of cell proliferation. 305 Bartosh et al. [39] have shown that proliferation-related genes are 306 downregulated in hMSCs upon aggregation. Thus, maximum cell densities in 307 spheroid-based cultures are limited to a certain spheroid size and to the number of 308 spheroids formed in the bioreactor, which limits their applicability for the hMSC 309 mass expansion. Moreover, large spheroids are exposed to diffusional limitations 310 (e.g., oxygen and nutrients), which is a major drawback in high cell density cultures. 311 Different studies have highlighted that spheroids exceeding 200–300 μm tend to 312 induce apoptosis or even undesired spontaneous differentiation due to nutrient or 313 oxygen limitations in the core of the spheroids [46–48]. Indeed, the size of the 314 spheroids can be controlled to a certain level by the fluid flow regime in a stirred 315 bioreactor, but this strategy provides another level of complexity, since spheroid 316 breakage procedures need to be introduced throughout the process. Various studies 317 have shown that the hydrodynamic stresses, the fluid velocities, and the Kolmogorov 318 length scale are very heterogeneously distributed in stirred bioreactors [12, 49, 50], 319 which may limit their effect on the spheroid size. Thus, spheroids are exposed to 320 fluctuating hydrodynamic stresses. Novel bioreactor designs are required that 321

322 provide homogenous shear stress levels for the formation and regulation of the
 323 spheroid sizes. Such bioreactor development or design studies can be supported by
 324 numerical models that allow for optimization of the fluid flow regarding these issues
 325 (i.e., homogenous hydrodynamic stress distribution).

326 2.2.2 Growth on Microcarriers

327 In order to overcome the limitations of the 2D culture systems, in 1967 van Wezel
 328 [51] developed the concept of MC-based cultivation systems. In these systems, the
 329 cells are expanded on the surface of small solid particles suspended in the cell culture
 330 medium by slow agitation. The MC-based expansion represents a unit operation in
 331 which both monolayer and suspension cultures are brought together. The MC
 332 surface is available for cell growth, while the mobility of MCs in the medium
 333 generates a homogeneity that is similar to the suspension environment used in
 334 traditional mammalian submerged cultures [52]. Thus, MC-based expansion sys-
 335 tems offer the following advantages:

- 336 1. A high surface to volume ratio, which can be further increased by increasing the
 337 MC concentration
- 338 2. A homogenous environment that allows various process parameters (e.g., pH,
 339 pO_2 , substrates and metabolites) to be both monitored and controlled
- 340 3. A possible scale-up of the MC-based expansion process within a suitable biore-
 341 actor series
- 342 4. Functionalization of the MC surface to improve cell attachment and in terms of
 343 hMSCs to retain a high “stemness”

344 Different MCs, which are usually spherical, have been tested or even developed
 345 over the years for the expansion of hMSCs (see Table 4). The MC types differ
 346 greatly in size (90–380 μm), core material (e.g., polystyrene, cellulose, dextran,
 347 gelatin), and surface coating (e.g., collagen, fibronectin, laminin, vitronectin). An
 348 overview of commercially available MCs, including their material properties, can be
 349 found in different reviews [15, 52, 53]. The core material and surface coating affect
 350 not only the MC settlement and cell growth but also the impeller speed which is
 351 required to hold the MCs in suspension and to guarantee sufficient mass transfer.
 352 Rafiq et al. [54] and Leber et al. [55] screened different MC types in small-scale
 353 bioreactors for hMSCs under predefined impeller speeds ($N_{js} = N_{st}$). Both found
 354 significant differences in cell attachment, cell growth, glucose consumption, and
 355 metabolite production depending on the MC type. They found that hBM-MSC grow
 356 best on collagen-coated MCs from Solohill and Synthemax II and ProNectin F MCs
 357 from Corning, something which comes as no surprise since these MCs are coated
 358 with collagen and fibronectin, respectively. Both coatings are components of the
 359 extracellular matrix, including the arginyl-glycyl-aspartic acid sequence which is
 360 well-known to promote cell attachment and cell growth of fastidious cells [56]. Dif-
 361 ferent studies have shown that the planar structure, including the material stiffness,
 362 nanotopography, and local curvature, can impact cell proliferation, maintenance of

Table 4 Bioreactors operated with microcarriers for the expansion of hMSCs from bone marrow and adipose tissue

	MSC source	Bioreactor system	WV	Microcarrier/coating	Culture medium	Agitation	Cell density	Ref.
t4.2	MSC	100 mL BellCo spinner	100 mL	Cytodex 1 and 3	DMEM+10% FBS	30 rpm	$0.65-0.68 \times 10^6$ cells/mL	[69]
t4.3	hBM-MSC	100 mL BellCo spinner	100 mL	Polystyrene-based MC	DMEM+10% FBS	30 rpm	0.08×10^6 cells/mL (2.7-fold)	[70]
t4.4		100 mL BellCo spinner	100 mL	Polystyrene-based MC	PRIME-XV SFM	30 rpm	0.31×10^6 cells/mL (10-fold)	[67]
t4.5		100 mL BellCo spinner	80 mL	Synthemax II	StemPro MSC	40 rpm	0.36×10^6 cells/mL (8-fold)	[68]
t4.6		100 mL BellCo spinner	15 mL	Plastic	DMEM+10% FBS	400 rpm	$0.10-0.50 \times 10^6$ cells/mL	[71]
t4.7		amb [®] 15	250 mL	Cytodex 1 and 3	MSCGM-CD	60 rpm	0.40 and 0.28×10^6 cells/mL	[72]
t4.8		BioBLU [®] 0.3c	100 mL	Plastic+PRIME-XV FN	DMEM+10% FBS	115 rpm	0.20×10^6 cells/mL	[73]
t4.9		BioBLU [®] 0.3c	100 mL	Plastic+PRIME-XV FN	DMEM+PRIME XV	115 rpm	0.70×10^6 cells/mL	[73]
t4.10		BioBLU [®] 0.3c	2.4 L	Collagen-coated MC	α MEM+10% hPL	25-35 rpm	0.40×10^6 cells/mL	[63]
t4.11		Mobius [®] CellReady 3L	2 L	CultiSpher G	Lonza medium+5% FBS	70 rpm	0.53×10^6 cells/mL	[74]
t4.12		UMI Vessel [®] SU 2L	50 L	CultiSpher G	α MEM+10% hPL	63 rpm	0.72×10^6 cells/mL	[75]
t4.13		BIOSTAT [®] STR 50L	50 L	Collagen-coated MC	DMEM+10% FBS	64-100 rpm	0.19×10^6 cells/mL	[63]
t4.14		Mobius [®] CellReady 50L	70 mL	Glass-coated MC	DMEM+10% FBS	30-75 rpm	0.38×10^6 cells/mL	[55]
t4.15	hTERT-MSC	100 mL Integra spinner	1 L	Glass-coated MC	DMEM+10% FBS	100 rpm	0.14×10^6 cells/mL	[55]
t4.16		1 L bioreactor Applikon						

(continued)

t4.17 **Table 4** (continued)

	MSC source	Bioreactor system	WV	Microcarrier/coating	Culture medium	Agitation	Cell density	Ref.
t4.18	MSC	125 mL Corning spinner	100 mL	ProNectin-F	Lonza medium+5% FBS	49 rpm	$0.58-1.25 \times 10^6$ cells/mL	[11, 62]
t4.19	hASC	100 mL BellCo spinner	80 mL	Synthemax II	StemPro MSC	40 rpm	0.19×10^6 cells/mL	[68]
t4.20		BioBLU [®] 5c	3.75 L	Polystyrene-based MC	MSC medium ATCC	25-35 rpm	0.04×10^6 cells/mL	[76]
t4.22		BioBLU [®] 5c	3.75 L	Collagen-coated MC		25-35 rpm	0.24×10^6 cells/mL	[76]
t4.23		UniVessel [®] SU 2L	2 L	ProNectin-F	Lonza medium+5% FBS	100-140 rpm	0.27×10^6 cells/mL	[62]
t4.24		BIOSTAT [®] STR 50L	35 L	ProNectin-F		50-66 rpm	0.31×10^6 cells/mL	[62]
	hTERT-ASC	125 mL Corning spinner	100 mL	ProNectin-F		49 rpm	0.63×10^6 cells/mL	[12]
		500 mL Corning spinner	300 mL	ProNectin-F		52 rpm	0.88×10^6 cells/mL	[12]




Fig. 3 Schematic representation of biochemical and physical parameters that have an influence on MC-based hMSC cultures

phenotype, and differentiation [57, 58]. Thus, many efforts are being made to develop GMP-grade biodegradable MCs. In general, cell attachment follows a Poisson distribution, where cell-to-MC ratios of one, two, or three result in theoretical probabilities of unoccupied MCs of 0.365, 0.135, and 0.05, respectively [59, 60]. Thus, theoretical cell densities for inoculation are in the range of between 3 and 5 cells per MC. After the cell attachment phase (4–20 h) under static or intermitted stirred conditions, every MC should have the same number of cells attached to its surface. However, in practice, this is not the case. As investigations by Ferrari et al. [61] have shown, suboptimal cell seeding results in the early formation of MC-cell aggregates that impair cell growth and characteristics (see Fig. 3). In addition, large MC-cell aggregates increase the risk of apoptotic cells due to the limited diffusivity of oxygen and nutrients into these aggregates. In fact, the impeller speed can be used to a certain extent to control such MC-cell aggregates, but the hydrodynamic stresses required for this task may also affect the cell growth and quality, especially of the outer cells. To minimize this risk, reliable models of the culture systems (“Digital Twins”) are necessary.

In addition to the selection of a suitable MC, the cell culture medium and its formulation also play a key role in the success of a MC-based cultivation. Many of the conventional culture media used for the expansion of hMSCs are defined basal media such as DMEM or α -MEM, which have to be supplemented with additives such as (I) proteins that mediate adhesion to the MC surface, (II) lipids for cellular anabolic purpose, and (III) growth factors and hormones to stimulate cellular proliferation and phenotype maintenance (see Table 4). Even though the disadvantages of serum are well-known, a lot of the hMSC cell culture media additionally contain 5–10% FBS. The highest cell densities generated in serum-containing medium (10% FBS) have been reported in the range of $0.14\text{--}0.65 \times 10^6$ cells/mL

389 for cultivations in stirred bioreactors up to benchtop scale. Schirmaier et al. [62] and
390 Lawson et al. [63] reported maximum cell densities of up to 0.3×10^6 cells/mL for
391 cultivations in stirred bioreactors at pilot scale with a cell culture medium
392 supplemented with 10% hPL or 5% FBS. Jossen et al. [11] even reported maximum
393 peak cell densities of up to 1.25×10^6 cells/mL for hMSCs from the adipose tissue in
394 spinner flask cultures with 5% FBS. A proven alternative to FBS is human platelet
395 lysate (5–15%). However, there is still a controversial discussion about whether the
396 cells retain their immunomodulatory properties and their full differentiation capa-
397 bilities [64–66]. Moreover, there is still a risk of human pathogens and their
398 components being poorly characterized. Therefore, there is a high level of interest
399 in serum- and xeno-free, chemically defined cell culture media. Various formula-
400 tions are now available on the market (e.g., Mesencult-XF, MSCGM-CD,
401 StemMACS MSC XF, etc.). The careful selection and supplementation of the XF
402 basal medium with suitable growth factors and hormones are important, especially
403 when working with MCs in stirred bioreactors. Special attention has to be paid to cell
404 attachment efficiency and shear stress sensitivity. It is an established fact that the
405 maximum cell densities ($0.04\text{--}0.40 \times 10^6$ cells/mL) and expansion factors that have
406 been achieved in stirred bioreactors with xeno- and serum-free cell culture media are
407 still lower than those achieved in serum-containing medium (see Table 4). Heathman
408 et al. [67] reported a maximum cell density of 0.31×10^6 cells/mL and an expansion
409 factor of 10 within 6 days of using PRIME-XV SF medium in a 100 mL BellCo
410 spinner flask. Carmelo et al. [68] even achieved a maximum cell density of up to
411 0.36×10^6 cells/mL but a slightly lower maximum expansion factor of 8 with the
412 StemPro MSC medium. Maximum cell densities of between 0.04 and
413 0.40×10^6 cells/mL were reported for the ATCC and MSCGM-CD medium in
414 the BioBLU 0.3c and BioBLU 5c bioreactor systems.

415 **3 Computational Fluid Dynamics as a Modern Tool** 416 **for Bioreactor Characterization**

417 Numerical methods, such as CFD, are widely used in the biotech industry to
418 investigate local properties (e.g., flow velocities, shear stresses) in bioreactors and
419 offer an alternative to experimental measurements (e.g., particle image velocimetry
420 (PIV), laser Doppler anemometry (LDA)), which are often time-consuming and
421 expensive. Thus, it is unsurprising that CFD is also a valuable tool for the charac-
422 terization of bioreactor systems used for the production of cell therapeutics. In the
423 following section, a short overview of the basic principle of CFD and various
424 investigations described in the literature are presented. In addition, a case study
425 will be discussed that demonstrates the use of CFD for the characterization of two
426 spinner flask types used for the MC-based hMSC expansion.

3.1 Modelling Approaches

427

The prediction of the fluid flow is based on solving mass, momentum, and energy 428
 conservation equations. This concept includes balances of accumulation, net inflow 429
 from convection and diffusion, and volumetric production within an infinitesimally 430
 small volume element. For most of the bioprocesses performed in the biotech 431
 industry, isothermal conditions (i.e., $T \approx \text{const.}$) can be assumed. As a result, the 432
 energy balance can be neglected. The mass and momentum equations for incom- 433
 pressible Newtonian media, which includes cell culture media, can be written as 434
 shown in Eq. (1) (*Continuity equation*) and Eq. (2) (*Momentum equation*). 435

$$\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho \vec{u}) = 0 \quad (1)$$

$$\frac{\partial (\rho \vec{u})}{\partial t} + \nabla \cdot (\rho \vec{u} \vec{u}) + \nabla p - \nabla \tau - \rho \vec{g} + \vec{F} = 0 \quad (2)$$

Based on the balancing concept and the spatial discretization of the fluid domain, 436
 local and time-dependent data (e.g., velocity gradients, hydrodynamic stress) can be 437
 calculated and used for the bioreactor design, the bioreactor characterization, and the 438
 process development. Thus, it is unsurprising that different modelling approaches 439
 are described in the literature for the CFD-based characterization of bioreactors used 440
 for the expansion of hMSCs (see Table 5). For example, Nienow et al. [71, 77], 441
 Kaiser et al. [50], Berry et al. [77], and Schirmaier et al. [62] performed single-phase 442
 simulations in the ambr 15, the disposable Corning spinner flask, the UniVessel SU 443
 2L, and the BIOSTAT STR 50L based on a *Reynolds-averaged Navier-Stokes* 444
 (*RANS*) approach in order to derive the fluid flow pattern and the hydrodynamic 445
 stresses acting under different process conditions. The *RANS* approach simplifies the 446
 formulation of the instantaneous velocities u by the sum of time-averaged velocities 447
 \bar{u} and their fluctuations u' , which reduces the computational efforts due to a lower 448
 grid resolution. In contrast, Collignon et al. [79] used a *large eddy simulation* (*LES*) 449
 approach, which only resolves macroscopic eddies, for the fluid flow characteriza- 450
 tion of a 250 mL mini-bioreactor, and their results were found to be in accordance 451
 with experimental data. Detailed information about the different numerical models 452
 can be found in high-grade textbooks [78–80]. The single-phase simulations do not 453
 provide information about the MC distribution and their dynamics in the system. As 454
 a result, Delafosse et al. [81], Kaiser et al. [50], and Jossen et al. [11, 12] used a 455
Euler-Euler approach in which the MCs were considered as secondary phase. 456
 However, this approach does not include discrete formulation of the particle phase 457
 and, therefore, only provides information for the entire phase. For this reason, Liovic 458
 et al. [82], Jossen et al. [12], and Delafosse et al. [83] described the use of a *Euler-* 459
Lagrange approach which provides a discrete particle formulation and the tracking 460
 of individual particles in the bioreactor. Thus, they calculated the circulation and 461
 residence times as well as the hydrodynamic stresses acting on individual particles 462
 and used this information for process development and characterization. 463

t5.1 **Table 5** Overview of studies dealing with CFD in order to characterize bioreactor systems for the expansion of hMSCs

t5.2	Simulation type	Bioreactor system	Title	Ref.
t5.3	Single-phase (RANS)	ambr 15	“The physical characterisation of a microscale parallel bioreactor platform with an industrial CHO cell line expressing an IgG4” and “Agitation conditions for the culture and detachment of hMSCs from microcarriers in multiple bioreactor platforms”	[71, 84]
t5.4		125 mL Corning spinner	“Fluid flow and cell proliferation of mesenchymal adipose-derived stem cells in small-scale, stirred, single-use bioreactors”	[50]
t5.5		125 mL Corning spinner	“Characterisation of stresses on microcarriers in stirred bioreactor”	[77]
t5.6		UniVessel SU 2L and BIOSTAT STR 50L	“Scale-up of adipose tissue-derived mesenchymal stem cell production in stirred single-use bioreactors under low-serum conditions”	[62]
t5.7	Single-phase (LES)	250 mL mini bioreactor	“Large-Eddy Simulations of microcarrier exposure to potentially damaging eddies inside mini-bioreactors”	[85]
t5.8	Multi-phase (Euler-Euler)	125 mL Corning spinner	“Fluid flow and cell proliferation of mesenchymal adipose-derived stem cells in small-scale, stirred, single-use bioreactors”	[50]
t5.9		UniVessel SU 2L	“Modification and qualification of a stirred single-use bioreactor for the improved expansion of human mesenchymal stem cells at benchtop scale”	[74]
t5.10		1.12 L HSB bioreactor	“Revisiting the determination of hydromechanical stresses encountered by microcarriers in stem cell culture bioreactors”	[81]
t5.11	Multi-phase (Euler-Lagrange)	125/500 mL Corning spinner	“Growth behavior of human adipose tissue-derived stromal/stem cells at small scale: Numerical and experimental investigations”	[12]
t5.12		125 mL Corning spinner	“Fluid flow and stresses on microcarriers in spinner flask bioreactors”	[82]
t5.13		20L RB bioreactor	“Euler–Lagrange approach to model heterogeneities in stirred tank bioreactors – comparison to experimental flow characterization and particle tracking”	[83]

464 3.2 Advanced Fluid Flow Characterization of Small-Scale 465 Spinner Flasks: A Case Study

466 In recent years, various publications in the scientific literature have demonstrated the
467 applicability of stirred SU bioreactors for the in vitro expansion of hMSCs. How-
468 ever, the in vitro expansion processes that provide clinically relevant cell numbers
469 were developed with cell culture media containing 10–20% FBS. The FBS made the

cells more robust and protected against the various stresses (e.g., hydrodynamic 470 stresses, physiochemical stresses, etc.) that occur during the in vitro expansion [86– 471 88]. The focus of this case study is on the biochemical engineering characterization 472 of the Corning spinner flasks (SP100 and SP300) with numerical methods (single- 473 and multi-phase CFD simulations). Special emphasis is placed on the suspension 474 criteria (N_{slu} and N_{sl}) which are investigated for their use in MC-based hMSC 475 expansions. The case study aims to highlight the use of CFD for the prediction of 476 biochemical engineering parameters and the establishment of a “Digital Twin” to 477 replicate real cultivation systems in silico. For this purpose, multi-phase simulations 478 with a continuum and discrete particle approach were performed, and time- 479 dependent hydrodynamic stresses were derived, based on the transient fluid flow. 480

3.2.1 Reactor Geometries and Model Approaches

481

The disposable Corning[®] spinner flasks (Corning, USA) were commercially avail- 482 able in two different sizes (125 and 500 mL; see Fig. 4). The rigid culture containers 483 were made from polycarbonate and were delivered pre-sterilized. The spinner flasks 484 were equipped with two angled side ports and a 70 mm or 100 mm top cap. The side 485 ports were used for gas exchange (O_2 , CO_2) in a standard cell culture incubator. 486

The main geometrical features of the two spinner flasks are summarized in 487 Table 6. For all numerical investigations, the working volumes were 100 mL 488 (SP100) and 300 mL (SP300), resulting in H_L/D ratios of 0.64 and 0.60, respec- 489 tively. Both spinner flasks were equipped with a paddle-like impeller consisting of a 490 blade and a magnetic bar. The impellers were directly mounted on the vessel lid and 491 were magnetically driven. 492

The fluid domain was modelled based on the geometrical data. Subdomains were 493 defined around the impellers in order to implement the impeller rotation using a 494 *moving reference frame* (MRF) or *sliding mesh* (SM) approach. In general, unstruc- 495 tured meshes consisting of tetrahedral elements (SP100 = 712,060 CV, SP300 = 496




Fig. 4 Small-scale SU Corning spinner flasks (125 and 500 mL) [89]. (a) Technical drawings with the main geometrical dimensions (mm). (b) Picture of the spinner flasks

t6.1 **Table 6** Overview of main geometrical features of the two Corning spinner flasks

t6.2			125 mL Corning spinner (SP100)	500 mL Corning spinner (SP300)
t6.3	V_{min}	mL	25	50
t6.4	V_{max}	mL	100	300
t6.5	D_R	mm	64	87
t6.6	$H_{L,max}$	mm	41	52
t6.7	d_R	mm	41	50
t6.8	h_R	mm	8	8
t6.9	H_L/D_R	–	0.65	0.60
t6.10	d_R/D_R	–	0.65	0.58
t6.11	h_R/D_R	–	0.13	0.09

497 2,073,079 CV) were used. In addition, a boundary layer along the vessel walls was
 498 implemented to improve the resolution of effects close to the vessel walls. The CFD
 499 simulations were performed using the *ANSYS Fluent* finite volume solver. The
 500 implemented pressure-based solver, with an absolute velocity formulation, was
 501 used for all simulations. The walls were treated as non-slip boundaries with standard
 502 wall functions. The liquid surfaces were treated as symmetry planes, with the fluid
 503 velocities normal to the face set to zero. The MCs were implemented in the
 504 simulations using (I) a *Euler-Euler granular* model or (II) a *Euler-Lagrange*
 505 approach with discrete particle modelling and tracking. In general, water ($\rho_L =$
 506 993 kg/m^3 , $\eta_L = 0.6913 \text{ mPa s}$ at 37°C) and the MC beads ($d_{p,mean} = 169 \text{ }\mu\text{m}$, $\rho_p =$
 507 $1,026 \text{ kg/m}^3$) were considered in the models. The initialization of the MCs was
 508 carried out either with settled beads (directly at the reactor bottom α_{MC} up to 0.63) or
 509 with beads that were homogenously distributed over the entire fluid domain. SIM-
 510 PLE (semi-implicit method for pressure-linked equations) and phase-coupled SIM-
 511 PLE algorithms were used for pressure-velocity coupling in the single- and multi-
 512 phase models. All simulations were run in parallel and solved on a computational
 513 cluster (up to 16 Intel Xeno[®] E5-2630 v4 CPU's @ 2.2 GHz, 64 GB RAM).

514 3.2.2 Results from Single-Phase Modelling

515 As shown in Fig. 5a, b, the steady-state fluid flow profiles in the two spinner flask
 516 types were similar due to their comparable geometrical ratios. In both cases, the
 517 highest fluid velocities occurred at the edges of the impeller blades and in the
 518 impeller wake. The maximum fluid velocities were slightly higher ($\leq 5\%$) than the
 519 theoretical u_{tip} , which could mainly be attributed to numerical uncertainties. How-
 520 ever, the observations are in agreement with literature data for disk stirrers. For
 521 example, Stoots et al. [90] and Wollny [91] demonstrated that the peak tangential
 522 velocities in the impeller wake can be up to ≈ 1.4 (experimental) and ≈ 1.5
 523 (numeric) times higher than the impeller speed. An area with relatively weak fluid
 524 velocities ($u/u_{tip} < 0.1$) was generated directly below the impeller ($r/R \pm 0.3$) in both
 525 systems. Thus, this area represented a critical zone for MC sedimentation. The




Fig. 5 Steady-state fluid flow inside the SP100 and SP300 [89]. The fluid flow pattern is presented in the vertical mid-plane for N_{Stu} -criterion (SP100 = 49 rpm (a), SP300 = 41 rpm (b)) as a combined vector and contour plot

observed MC transport from the outer part of the vessel to the vessel center was 526
 mainly driven by the induced secondary flow. Similar findings were also reported by 527
 Berry et al. [77], Liovic et al. [82], and Venkat et al. [92] in other types of small-scale 528
 spinner flasks. 529

In addition to the stationary fluid flow, the time-dependent behavior of the fluid 530
 velocities was simulated for both systems. Compared to the stationary flow field, the 531
 occurrence of vortices at the back of the impeller blades becomes visible. According 532
 to the definition of turbulence, these vortices occur stochastically and follow the 533
 main fluid flow convectively. Similar findings were also reported by Ismadi et al. 534
 [93] by means of PIV measurements of small-scale spinner flasks with a slightly 535
 different impeller geometry ($d_R/D = 0.88$). The fluctuations in the fluid velocities 536
 also become visible when analyzing the fluid velocities at different positions near the 537
 impeller (see Fig. 6). It is obvious that after a certain number of stirrer rotations, a 538
 “quasi-periodic” fluid movement was obtained. However, the fluctuations in the 539
 lower part of the vessel were higher compared to those near the fluid surface. This 540
 was not surprising because of the location of the impeller bar which periodically 541
 crossed the different areas. Thus, higher fluid velocity gradients occurred in the 542
 lower part of the spinner flasks and increased the local turbulences. However, 543
 depending on the strength of the velocity gradients, an effect on the cells may be 544
 possible. Berry et al. [77] showed that higher fluid velocity fluctuations can result in 545
 local hydrodynamic stresses (10^{-3} – 10^{-1} Pa) for the cells in small-scale spinner 546
 flasks which are up to three times higher. 547

Since a number of mathematical assumptions were used for the CFD modelling, 548
 stereoscopic PIV measurements were performed to verify the CFD-predicted fluid 549
 flow pattern (see Fig. 7). A detailed description of the experimental setup and 550
 procedure for stereoscopic PIV measurements can be found in Jossen et al. 551
 [12]. For a quantitative comparison of the individual velocity components, the 552




Fig. 6 Time-dependent courses of the fluid velocities at eight different locations within the SP100 [89]. (a) Schematic representation of the different locations within the SP100 ($= 49 \text{ rpm } N_{slu}$). (b) Dimensionless fluid velocity at the different positions during stirrer rotation




Fig. 7 CFD model verification by experimental PIV measurements in the SP100 and SP300 [89]. Quantitative comparison of CFD-predicted and PIV-measured fluid velocity components (\vec{u} , \vec{v} , \vec{w}) in the SP100 (a) and SP300 (b)

553 CFD-predicted and PIV-measured data were compared along dimensionless radial
 554 coordinates ($0.5-1.0 \text{ } r/R$) at an axial position of $h/H_L = 0.1$. The comparison of the
 555 velocity components in the SP100 revealed only minor differences for \vec{v} (up to
 556 7.5%) and \vec{w} (up to 8.7%). However, the CFD velocity profiles were well captured,
 557 and the overall agreement of PIV and CFD was satisfactory, with findings consistent
 558 with those of Kaiser et al. [50]. A comparison of the fluid velocities in the SP100 was

only possible for r/R between 0.50 and 0.82 due to the pronounced curve of the vessel surface. The differences between CFD and PIV can be accounted for by measurement uncertainties based on optical phenomena (light refraction and distortion) and the restricted measurement accuracy directly at the edges of the impeller bar (pixel resolution of the camera chip). Thus, direct comparison to the fluid velocities in direct proximity to the impeller is difficult. All three velocity components in the SP300 were well captured by the PIV measurements. The greatest differences (7.9–15%) were found for \bar{u} between r/R 0.70 and 0.85. Hence, it can be concluded that the single-phase CFD model provides reliable fluid flow predictions in both spinner flask types.

3.2.3 Results from Multi-phase Modelling

Oxygen Mass Transfer

Oxygen represents a critical parameter in the cultivation of human cells because it is essential for mitochondrial respiration and oxidative phosphorylation. Hence, the determination of the oxygen mass transfer (OTR) represents an important aspect. However, many of the small-scale bioreactor systems frequently used for the expansion of hMSCs are not equipped with oxygen sensors, which makes it impossible to experimentally determine the oxygen transfer. In such cases, multi-phase CFD simulations can be used to estimate the oxygen mass transfer coefficient (k_{La}), which is shown in the following representative for the SP100.

The multi-phase VOF approach, which takes the headspace into account, was used for the prediction of the k_{La} in the spinner flasks. Figure 8 (a) shows the stationary fluid flow pattern ($N = 49$ rpm) obtained from the multi-phase VOF model, without significant differences to that derived from the single-phase simulations (see Sect. 3.2.2). This conformity between the single and multi-phase simulations was due to the fact that the transport equations for mass and momentum were corrected only at the phase boundary where both the liquid and the gaseous phase were within the control volume. Since only low impeller speeds (≤ 120 rpm) were used in the SP100, marginal changes in the fluid surface with relative low interactions between the liquid and gaseous phases occurred. As a result, the multi-phase VOF model also provided reliable predictions for the fluid flow as well as the fluid surface.

The calculation of the k_{La} value by means of CFD is usually performed in surface-aerated systems using Higbie’s penetration model. In this approach, the mass transport is modelled by surface renewal, whereby a characteristic contact time between fluid elements and the phase boundary is calculated (see Eq. (3)).




Fig. 8 Fluid flow pattern (a) derived from multi-phase CFD simulation and simulated cell growth (q_{O_2}) based on data from CFD simulation (b)

$$k_L = 2 \cdot \sqrt{\frac{D_{O_2}}{\pi \cdot t_c}} \quad (3)$$

595 Since the fluid flow in the SP100 was mainly tangentially oriented, the contact
 596 time was calculated based on the sum of the fluid velocities (w/o the axial component
 597 \vec{v}) and the mean perimeter of the vessel (see Eq. (4)).

$$t_c = \frac{\pi \cdot d_R}{\sqrt{u^2 + w^2}} \quad (4)$$

598 The specific interface area (a) was defined according to Zhang et al. [94] as the
 599 area with a liquid volume fraction of $\alpha_L = 0.5$ divided by the total liquid volume (see
 600 Eq. (5)).

$$a = \frac{A_{\alpha_L=0.5}}{V_L} \quad (5)$$

601 Using this model approach, $k_L a$ values of between 2.6 and 4.2 h^{-1} were predicted
 602 for impeller speeds between 49 and 120 rpm ($= u_{tip}$ 0.10–0.26 m/s). Compared to
 603 experimentally measured $k_L a$ values (2.6–4.3 h^{-1}), which were measured in a SP100
 604 specially equipped with an optical pO_2 sensor, only minor differences were found.
 605 Consequently, the multi-phase CFD model provided reliable predictions about the
 606 oxygen mass transfer in the spinner flasks, especially due to the moderate fluid flow
 607 conditions and the surface aeration.

608 Under consideration of the specific oxygen consumption rate
 609 ($0.22\text{--}2.5 \times 10^{-17}$ mol/cell/s [89, 95, 96]) or a corresponding yield coefficient for

hMSCs in combination with the oxygen mass transfer, cell growth can be calculated 610
 based on the oxygen consumption during the hMSC expansion process (see Eq. (6)). 611

$$\frac{dX_{MC}}{dt} = k_L a (c_{O_2}^* - c_{O_2}) \cdot Y_{X/O_2} \quad (6)$$

An example of such an oxygen-dependent growth simulation, which was 612
 performed with MATLAB, is shown in Fig. 8b. It is recognizable that the cell 613
 density can be simulated based on the current oxygen concentration in the SP100 614
 with a satisfactory accuracy. A good correlation (RMSD = 0.05) was obtained 615
 between the simulated and the experimental cell density which was measured offline 616
 at the beginning and end of the cultivation. 617

Microcarrier Distribution Based on a *Euler-Euler Granular* Approach 618

In MC-based hMSC expansion processes, the sufficient suspension of the MCs is an 619
 important aspect since a fully suspended state is desired [96–98]. However, since 620
 hMSCs are sensitive to hydrodynamic stresses [99–105], the impeller speed and 621
 corresponding power input are limited to a certain level, depending on the MC 622
 concentration. Therefore, the characterization of the MC-distribution and the deri- 623
 vation of the acting hydrodynamic stresses are important. One possible numeric 624
 approach to obtain these data is the use of a *Euler-Euler granular* model in which the 625
 two phases are considered as interpenetrating continua. Therefore, mass and momen- 626
 tum are treated individually for each phase. Figure 9 shows an example of the 627
 volume-weighted frequency distribution of the dimensionless MC solid fractions 628
 (α/α_{mean}) in the two spinner flasks for a MC solid fraction of 0.1% and for the 629
 suspension criterion $N_{s,lu}$ (SP100 = 49 rpm, SP300 = 41 rpm). As expected, the 630
 highest MC volume fractions were, in both cases, found directly below the impeller 631
 in the weak mixing zone ($r/R \pm 0.3$; see also Sect. 3.2.2). This observation is not 632
 surprising because of the definition of the $N_{s,lu}$. The spatial position of the 633
 CFD-predicted deposits agreed well with those made by Kaiser et al. [50]. They 634
 also showed a good correlation of their data with experimental observations, which 635
 demonstrates the applicability of the *Euler-Euler granular* model for the prediction 636
 of the MC distribution in bioreactors. The CFD-derived volume-weighted frequency 637
 distribution of the dimensionless MC volume fractions showed comparable MC 638
 homogeneity for the two spinner flask types (see Fig. 9c). The fronting of the 639
 distributions clearly indicates zones with low MC volume fractions. These zones 640
 were mainly determined near the fluid surface, representing the sedimentation 641
 boundary. The similar conditions at the vessel bottom can mainly be explained by 642
 the same off-bottom clearance ($h_R = 8$ mm), whereas the MC distribution over the 643
 entire vessel volume is mostly affected by the d_R/D ratio. The results from the two 644
 spinner flasks demonstrate that the *Euler-Euler granular* model provides reliable 645
 predictions for MC distribution. However, due to the continuum formulation of the 646




Fig. 9 Contour plots of the dimensionless MC volume fraction (a, b) and volume-weighted frequency distribution (c) at N_{sLu} (SP100 = 49 rpm, SP300 = 41 rpm)

647 model, information on individual particles and their circulation and residence times
 648 in different high shear zones cannot be obtained.

649 Microcarrier Tracking Based on a *Euler-Lagrange* Approach

650 *Euler-Lagrange* simulations allow the spatial distribution of discrete MC particles to
 651 be derived. Based on this information, the circulation time (t_{cir}), the residence time
 652 (t_{res}), and the hydrodynamic stresses acting on the particles can be calculated. Data
 653 from such an *Euler-Lagrange* simulation is shown representatively in the following
 654 figure for the SP100. Figure 10a, b shows an example of the fluctuating forces acting
 655 on individual MCs during impeller motion. It is obvious that the acting forces
 656 fluctuated in the order of 100. Thus, each particle has its own history in terms of
 657 hydrodynamic stress, which means that some particles are exposed to a certain
 658 hydrodynamic stress level longer and/or more often than others. Compared to the
 659 *Euler-Euler granular* approach, which allows volume-weighted data to be derived,
 660 the *Euler-Lagrange* approach gives a discrete description per MC.

661 The particle data can further be processed to derive the force distribution for
 662 specific locations or to calculate the circulation and residence times. For this
 663 purpose, the two spinner flask types were vertically divided into four zones ($\Delta h/$
 664 $H_L \approx 0.25$). Figure 11 exemplifies the SP100, showing the force distribution in the
 665 four defined spinner segments. It is obvious that logarithmic normal distributions




Fig. 10 Force acting on the MCs during the impeller motion. Time-dependent force diagrams are shown representatively for two individual particles in the SP100 ($N = 49$ rpm)

were obtained where highest forces occurred in the lowest segment. Thus, cells on 666
 MCs were more stressed in the lowest spinner segment. This observation was also 667
 supported by the fact that the highest probability of the presence of MCs was in the 668
 lowest spinner segment. However, the effects of the hydrodynamic stresses in the 669
 different zones depended heavily on the particle circulation and residence times, 670
 demonstrating the dynamics and complexity of the systems. For this reason, 671
 circulation times and residence times were calculated for each individual spinner segment 672
 based on the particle tracking data and were subsequently averaged over the four 673
 segments (see Table 7). As expected, the circulation times (2.7–11.5 s) decreased 674
 proportionally to the residence times (0.74–4.94 s) as the impeller speed was 675
 increased. Interestingly, the proportionality constants for the SP100 ($= 0.54$) and 676
 the SP300 ($= 0.49$) were quite similar. This observation can be ascribed to the 677
 comparable fluid flow conditions. The calculated mean forces were inversely 678
 proportional to the circulation and residence times. This finding is not unexpected since 679
 the specific power input, which can be calculated based on the torque acting on the 680
 impeller during the CFD simulation, increased by approximately the 3rd power in 681
 both spinner flask types. Interestingly, the mean values of particle forces did not 682
 change significantly between the lower impeller speeds ($N < N_{slu}$) and the two 683
 suspension criteria, even though the circulation and residence times decreased by up 684
 to 50%. Impeller speeds exceeding N_{slu} and N_{sl} resulted in a slight decrease of the 685
 circulation times, although the related particle forces increased by exponents of 686
 0.07–0.12 in respect of the resulting specific power input. 687

Comparable observations for the specific power input are also possible when 688
 considering the local normal and shear stresses, which can be calculated according to 689
 Wollny [91]. The volume-weighted mean values of the local normal and shear 690
 stresses were in a comparable range in both spinner flask types for impeller speeds 691
 between N_{slu} and N_{sl} . Consequently, comparable conditions in terms of hydrody- 692
 namic stresses can be expected for cultivations in the resulting specific power input 693
 range of 0.3–1.1 W/m^3 . Another popular method for evaluating hydrodynamic stress 694




Fig. 11 Force distributions in the different spinner segments

695 is based on the Kolmogorov length scale, which can be calculated from CFD
 696 simulations. While cells in suspension are assumed to only be affected by turbulent
 697 eddies of comparable size, those growing on the surface of an MC appear to be more
 698 shear sensitive. Croughan et al. [106] found that cell damage became significant
 699 when the smallest turbulent eddies were approximately two-thirds of the size of an
 700 MC. However, to apply Kolmogorov's theory, the fluid flow must be very turbulent
 701 ($Re > 10^4$). The flow in the two-spinner flasks can be described as moderately
 702 turbulent. However, the calculated maximum dissipation rates were higher by a
 703 factor of two in the impeller swept volume than in the bulk. As expected, the smallest
 704 turbulent eddies were found for the highest tested impeller speeds, with values
 705 between 30 and 47 μm . In terms of the suspension criteria, the minimum values
 706 were predicted between 60 and 76 μm , which is much lower than the proposed
 707 two-thirds MC size. In contrast, the volume-weighted mean values were slightly
 708 higher than the MC size, which demonstrated that only a small proportion of the
 709 turbulent eddies are comparable in size to the MCs. This lowers the risk that the MCs
 710 might come into contact with these detrimental eddies. However, this fact also

Table 7 Overview of the main biochemical engineering parameters derived from the CFD simulations

N [rpm]	u_{tip} [m/s]	Re	P/V [W/m ³]	$t_{cir.}$ [s]	$t_{res.}$ [s]	$l_{\lambda}^{(a)}$ [μm]	$\tau_{nl}^{(b)}$ [10 ⁻³ Pa]	$\tau_{nn}^{(b)}$ [10 ⁻³ Pa]	$F^{(c)}$ [10 ⁻⁵ N]
<i>Corning 125 mL spinner (SP100)</i>									
25	0.05	715	0.07	11.5	4.9	130/ 530	2.72/79	0.79/43	0.75
49 N_{s1u}	0.11	1,402	0.63	6.5	2.4	66/ 228	5.39/169	1.15/108	0.85
60 N_{s1}	0.13	1,717	1.12	6.0	1.9	60/ 191	6.62/211	1.32/138	0.91
120	0.26	3,434	7.56	4.0	0.9	30/ 111	12.91/437	2.24/301	1.82
<i>Corning 500 mL spinner (SP300)</i>									
20	0.05	841	0.05	10.0	4.2	136/ 546	2.04/214	0.30/138	0.83
41 N_{s1u}	0.11	1,724	0.33	6.2	2.6	76/ 295	4.00/481	0.69/362	0.89
52 N_{s1}	0.14	2,186	0.61	5.9	1.6	66/ 282	5.00/679	0.87/473	1.04
100	0.26	4,204	3.70	2.7	0.7	47/ 181	9.26/ 1,350	1.70/872	2.10

^aVolume -weighted minimum/mean values of turbulent Kolmogorov length scale^bLocal shear (τ_{nl}) and normal (τ_{nn}) stress for volume-weighted mean/maximum values^cMean values of acting particle force weighted by number

depends heavily on the resulting circulation and residence times of the MCs. In both cases, the mean volume-weighted values for the highest tested impeller speeds were much closer to the detrimental theoretical value of 141 μm. Even though such eddies occurred at the suspension criteria, the frequency with which the MCs were exposed to such eddies was much lower due to the lower circulation times and residence times.

3.2.4 Linking of CFD-Derived Data with Cultivation Studies

In order to link the CFD-derived engineering data with cell biological aspects, cultivation studies in the two spinner flask types at different impeller speeds were performed. The results of the cultivation studies with hMSCs from the adipose tissue are summarized in Table 8. It is obvious that the different hydrodynamic stress levels have a significant effect on the cell growth in both spinner flask types. Highest living cell densities were achieved, of up to $1.68 \pm 0.36 \times 10^5$ cells/cm² ($= 6.25 \pm 0.35 \times 10^5$ cells/mL, EF 56) and $2.46 \pm 0.16 \times 10^5$ cells/cm² ($= 8.77 \pm 0.66 \times 10^5$ cells/mL, EF 81), in the SP100 and SP300 when working at $N_{s1u} \leq N \leq N_{s1}$ (SP100 = 49–63 rpm, SP300 = 41–52 rpm). The peak living cell densities in the SP300 were on average up to 40% higher than those in the SP100. Although the two spinner

t8.1 **Table 8** Summary of cultivation results with hMSCs from the adipose tissue in the SP100 and SP300

t8.2	N [rpm]	Living X_{max} [10^5 cells/cm ²]	EF	μ [d ⁻¹]	t_d [d]	q_{Glc} [pmol/ cell/d]	q_{Lac} [pmol/ cell/d]	q_{Amm} [pmol/ cell/d]
t8.3	<i>Corning 125 mL spinner (SP100)</i>							
t8.4	25	1.05 ± 0.06	35.0	0.6 ± 0.0	1.1 ± 0.1	13.2 ± 2.3	20.7 ± 2.7	8.8 ± 0.3
t8.5	49 N_{sLu}	1.67 ± 0.12	55.6	0.7 ± 0.0	1.0 ± 0.0	10.6 ± 1.6	35.2 ± 1.9	6.1 ± 0.4
t8.6	60 N_{sI}	1.68 ± 0.36	56.0	0.7 ± 0.1	0.9 ± 0.1	9.8 ± 0.8	30.3 ± 1.0	6.2 ± 0.3
t8.7	120	0.60 ± 0.04	20.1	0.5 ± 0.1	1.5 ± 0.4	35.0 ± 1.6	88.8 ± 5.2	16.5 ± 0.3
t8.8	<i>Corning 500 mL spinner (SP300)</i>							
t8.9	20	1.36 ± 0.57	45.2	0.5 ± 0.1	1.3 ± 0.1	21.0 ± 0.9	28.6 ± 9.9	14.7 ± 0.2
t8.10	41 N_{sLu}	2.46 ± 0.16	81.9	0.7 ± 0.0	1.0 ± 0.0	15.5 ± 0.6	40.6 ± 1.8	10.6 ± 0.5
t8.11	52 N_{sI}	2.43 ± 0.66	81.1	0.7 ± 0.0	1.0 ± 0.0	11.8 ± 1.2	35.3 ± 3.3	9.7 ± 0.4
t8.12	100	1.25 ± 0.29	41.8	0.5 ± 0.1	1.3 ± 0.0	20.8 ± 9.8	88.6 ± 2.1	19.0 ± 1.4

728 flask types had comparable geometrical ratios, the hydrodynamic stresses in the
729 SP100 were higher at the suspension criteria. In fact, the absolute hydrodynamic
730 stresses over time were higher due to the lower circulation times, which increase the
731 risk that the cells on the MCs are more frequently exposed to detrimental stresses. At
732 the same time, the residence times, and therefore also the exposure times, of the MCs
733 to the hydrodynamic stresses were shorter, as the multi-phase simulations have
734 indicated. In both cases, the peak cell densities were in the same range as cell
735 densities measured in planar static cultures at maximum confluency ($\approx 2.9 \times 10^5$
736 cells/cm²), in which the cells were expanded in parallel. This result indicates that the
737 cells cultivated at $N_{sLu} \leq N \leq N_{sI}$ are mainly restricted by the available growth
738 surface. In contrast, significant lower cell densities were achieved at lower and
739 higher impeller speeds. A peak living cell density of $1.05 \pm 0.06 \times 10^5$ cells/cm²
740 ($= 4.49 \pm 0.06 \times 10^5$ cells/mL, EF 35) and $1.36 \pm 0.57 \times 10^5$ cells/cm² ($= 4.48 \pm$
741 0.57×10^5 cells/mL, EF 45) was determined for the SP100 and SP300 at 25 rpm and
742 20 rpm, respectively. These peak cell densities are up to 84% lower than those at
743 $N_{sLu} \leq N \leq N_{sI}$. This observation may have been caused by the higher amount of
744 sedimented MCs and the increased MC-cell aggregate formation (see also [12]). The
745 viability of the cells on the MCs was always >99%. This was not surprising as dead
746 cells detach from the MC surface. Thus, the increase in dead cells in the supernatant
747 depends on the cell detachment from the MC surface and the die-off of cell in the
748 supernatant.




Fig. 12 Dependency of the specific growth rate on the CFD-derived specific power input (a) and the Kolmogorov length scale (b) [89]. Data from other SU bioreactors were obtained from the literature: UniVessel SU 2L [62, 74], UniVessel SU 2L modified [74], Mobius CellReady 3L [89, 108], BIOSTAT STR 50 L [62, 89], BIOSTAT RM 2L [11], Mobius CellReady 3L [63], ambr 15 [109], 100 mL BellCo spinner [109], 250 mL DASbox bioreactor [73].

By considering q_{Glc} , it becomes clear that the lowest values were obtained for 749
 impeller speeds in the range of $N_{s1u} \leq N \leq N_{s1}$ in both cases. This is due to the 750
 efficient metabolization of glucose under these hydrodynamic conditions. The 751
 calculated values for the hMSCs correspond to those determined by Rafiq et al. 752
 [54] and Heathmann et al. [107] in different cell culture media. The highest q_{Glc} 753
 (21–35 pmol/cell/d) were found at the highest impeller speeds. The relationship 754
 between the q_{Glc} and the specific power input can be expressed by a statistical, 755
 logarithmic function of 3rd order. Similar correlations were also found for q_{Lac} and 756
 q_{Amn} . However, such statistical correlations are only valid for the investigated P/V 757
 range. Values of up to 193% and 170% higher than those in the spinner flasks at N_{s1u} 758
 and N_{s1} were determined for q_{Lac} and q_{Amn} at the highest impeller speeds. These 759
 higher values indicated that the cells are more stressed at higher impeller speeds as a 760
 result of the higher hydrodynamic stresses. The different correlations obtained were 761
 used as initial parameters for the cell growth modelling (see Sect. 4.2). 762

Figure 12a, b shows the relationship between the overall mean specific growth 763 AU4
 rate and the specific power input and Kolmogorov length scale, respectively. The 764
 parabolic curve profile of the specific growth rate shows optimal cell growth for N_{s1u} 765
 $\leq N \leq N_{s1}$. For specific power inputs between 0.33 and 1.12 W/m³, maximum μ 766
 between 0.70 and 0.74 d⁻¹ were achieved. This function also correlates well with 767
 literature data from other SU bioreactors. Similar relationships to the specific power 768
 input were also established for the Kolmogorov length scale, where a linear relation 769
 was found. Thus, CFD-derived hydrodynamic stress data can be used to find 770
 correlations between biochemical engineering and cell cultivation aspects and to 771
 define optimum cultivation conditions for MC-based hMSC expansion processes. 772

773 4 Mathematical Growth Modelling of MC-Based hMSC 774 Expansions

775 The development of mathematical growth models to describe or predict hMSC
776 growth is gaining in importance. This is not surprising since the cell material is
777 often limited and isolated directly from the patient. Thus, the prediction of the cell
778 growth depending on patient data (e.g., age, health status) is an important aspect,
779 especially for autologous therapies. The following section gives a brief overview of
780 different growth models described in the literature for the expansion of hMSCs. In
781 addition, a case study is presented and discussed, which presents an unstructured,
782 segregated growth model for the expansion of hMSCs on MCs.

783 4.1 Modelling Approaches

784 Table 9 gives an overview of publications describing different model approaches for
785 the simulation of the hMSC growth. For example, Higuera et al. [110], Dos Santos
786 et al. [111], and Jossen et al. [12] used kinetic growth models based on Monod-type
787 kinetics. Higuera et al. focused in its formulation only on the substrate/metabolite
788 inhibition, whereas Dos Santos and Jossen et al. introduced terms that considered
789 cell contact inhibition. All models allowed the hMSC cell growth and substrate

t9.1 **Table 9** Overview of hMSC growth models described in the literature

t9.2	Model type	Title	Ref.
t9.3	Monod-type kinetic models	“Quantifying in vitro growth and metabolism kinetics of human mesenchymal stem cells using a mathematical model”	[110]
t9.4		“Ex-vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia”	[111]
t9.5		“Growth behavior of human adipose tissue-derived stromal/stem cells at small scale: numerical and experimental investigations”	[12]
t9.6	Population balance models	“Population balance modelling of stem cell culture in 3D suspension bioreactors”	[112]
t9.7		“Experimental analysis and modelling of bone marrow mesenchymal stem cells proliferation”	[113]
t9.8		“A mathematical framework to study the effects of growth factor influences on fracture healing”	[114]
t9.9		“Modelling of in vitro mesenchymal stem cell cultivation, chondrogenesis and osteogenesis”	[115]
t9.10	Cellular automaton models	“Population dynamics of mesenchymal stromal cells during culture expansion”	[116]
t9.11		“Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density”	[117]
t9.12	Cell-based podia model	“Spatial organization of mesenchymal stem cells in vitro – results from a new individual cell-based model with podia”	[118]

consumption to be described based on the experimental setup investigated. In contrast to the Monod-type models, Bartolini et al. [112], Mancuso et al. [113], Bailon-Plaza et al. [114], and Geris et al. [115] used population balance models. For example, Bailon-Plaza et al. [114] included different cell populations in their model in order to describe not only hMSC proliferation but also chondrogenic and osteogenic differentiation. However, all models included parameters strongly influenced by various biological aspects. A discrete formulation of the cells was given by Schellenberg et al. [116] and Cholewa et al. [117], who both used cellular automaton models to describe the hMSC cell growth. However, these models did not include a metabolic description of substrate consumption and metabolite production, which can have an inhibitory effect on the cell growth. Hoffmann et al. [118] developed an individual cell-based model with podia, which is able to quantitatively describe the spatio-temporal organization of MSC culture. They modelled discrete cells and considered their orientation on a planar surface. Hence, the model considers the effects of contact inhibition and the organization and orientation of the cell monolayer. However, the model does also not reflect the metabolization of different substrates or the production of inhibitory metabolites.

4.2 Kinetic Growth Model for the MC-Based hMSC Expansion: A Case Study

Based on theoretical considerations, an unstructured, segregated, simplistic growth model was developed for the MC-based hMSC expansion in the SP100 and SP300. Theoretically, the entire expansion process can be divided into four steps: (I) cell sedimentation and initial attachment, (II) cell spreading and migration, (III) mitotic cell division, and (IV) cell growth arrest due to contact or substrate inhibition), which partially ran in parallel. The general concept of the growth model and the factors that influence the MC-based culture are shown in Fig. 13. During the cultivation period, the formation of MC-cell aggregates is promoted due to the increasing number of cells per bead and periodic particle interactions. The rate of the MC-cell aggregate formation is influenced by the frequency and strength of the hydrodynamic stresses. However, the rate of MC-cell aggregate formation was not considered in the current version of the MC-based growth model because the aggregation process is very complex and depends on many physical and biological parameters. Due to the fact that hMSC growth is anchorage-dependent, possible formation of spheroids in the suspension was not considered in the model. This simplification was justified since no spheroid formation was observed in the MC-based expansions. Thus, it can be assumed that cells in suspension do not contribute to an increase in the overall cell number, with cell growth restricted to the MC surface. To define the starting conditions, it was assumed that initial cell attachment took place during the cell attachment phase, which can be described by the attachment constant k_{at} . After the cells had attached themselves to the MC




Fig. 13 Schematic representation of different phases and influencing factors during the MC-based expansion of hMSCs. The MC-based expansion can be divided into four phases: (I) cell sedimentation/attachment, (II) cell spreading/migration, (III) mitotic cell division, (IV) MC-cell aggregate formation and cell growth arrest, with some running in parallel

830 surface, a short cell adaption phase was considered before the cells began to
831 proliferate.

832 The cell adaption phase was considered by introducing the coefficient α (see
833 Eq. (7)),

$$\alpha(t) = \frac{t^n}{t^n + t^n} \quad (7)$$

834 where t_l defined the lag time or adaption time and the point at which $\alpha(t)$ is half of the
835 maximum. The exponent n affects the slope of $f(\alpha(t))$. If $n = 1$, $\alpha(t)$ is described by
836 Michaelis-Menten kinetics. Otherwise, a sigmoidal curve is obtained that becomes
837 steeper as n increases. Both variables can be obtained from experimental growth
838 studies.

839 The specific cell growth rate (μ) was calculated based on Monod-type kinetics.
840 Hence, glucose (Glc), lactate (Lac), ammonium (Amn), and the available growth
841 surface (X_{max}) were considered to be influencing factors (see Eq. (8)). However,
842 investigations indicated that cell growth restriction based on maximum available
843 growth surface does not follow a normal Monod-type kinetic. This fact can mainly
844 be ascribed to cell migration during cell growth. Thus, the effect of the growth
845 surface restriction term becomes more significant towards the end of the cell growth
846 phase. For this reason, the exponent n was also introduced in Eq. (8).

$$\mu = \mu_{max} \cdot \left(\frac{Glc}{K_{Glc} + Glc} \right) \cdot \left(\frac{K_{Lac}}{K_{Lac} + Lac} \right) \cdot \left(\frac{K_{Amn}}{K_{Amn} + Amn} \right) \cdot \left(\frac{X_{max}^n - X_A^n}{X_{max}^n} \right) \quad (8)$$

847 The cell number on the MC surface (X_A) increased through mitotic cell division
848 and the attachment of cell from the suspension (see Eq. (9)). However, this increase
849 in cell number was affected by the detachment of hMSCs from the planar growth
850 surface, which was accounted for by the detachment constant ($-k_{det}$).

$$\frac{dX_A}{dt} = \alpha \cdot \mu \cdot X_A + k_{at} \cdot \frac{(X_{max}^n - X_A^n)}{X_{max}^n} \cdot X_{Sus} - k_{det} \cdot X_A \quad (9)$$

However, the detachment constant $-k_{det}$ is strongly affected by hydrodynamic forces and is therefore variable for different specific power inputs. As mentioned previously, cell growth in the suspension is negligible, and, therefore, changes in cell concentration will only be affected by attachment to or detachment from the MC surface (see Eq. (10)).

$$\frac{dX_{Sus}}{dt} = k_{det} \cdot X_A - k_{at} \cdot \frac{(X_{max}^n - X_A^n)}{X_{max}^n} \cdot X_{Sus} \quad (10)$$

Contrary to the growth restriction based on the specific growth rate, glucose consumption was only limited by the glucose concentration itself (see Eq. (11)). Consequently, glucose consumption was the result of the glucose uptake by the mitotic cells and the maintenance metabolism of mitotic and non-mitotic cells (X_V). A step response (δ_{Glc}) was implemented in Eq. (11) to avoid negative glucose concentrations.

$$\frac{dGlc}{dt} = -\frac{1}{Y_{x/Glc}} \cdot \alpha \cdot \mu \cdot \frac{(X_{max}^n - X_A^n)}{X_{max}^n} \cdot X_A - m_{Glc} \cdot \delta_{Glc} \cdot X_V \quad (11)$$

L-glutamine (*Gln*) consumption was not considered in this model since metabolic measurements from the experiment indicated that *Gln* is not a limiting factor. Moreover, UltraGlutamine (L-alanyl-L-glutamine) is used in most stem cell culture medium for which the model was developed and had undergone a series of complex degradation steps (i.e., (I) cleavage by extracellular peptidases and (II) degradation of free L-glutamine or absorption into the cells and metabolization). The production of lactate (*Lac*) and ammonium (*Amn*) was accounted for by Eqs. (12) and (13).

$$\frac{dLac}{dt} = q_{Lac} \cdot X_A \cdot \alpha + p_{Lac} \cdot X_V \quad (12)$$

$$\frac{dAmn}{dt} = q_{Amn} \cdot X_A \cdot \alpha + p_{Amn} \cdot X_V \quad (13)$$

The validity of the unstructured, segregated growth model was tested for MC-based hMSC expansions in the SP100 and SP300 (each $n = 3$), which were performed at N_{s1u} (SP100 = 49 rpm, SP300 = 41 rpm). All growth-related simulations were performed with MATLAB 2019b (MathWorks Inc.) where the model equations were solved using the *ode15s* solver (Intel Core i-7 CPU @ 2.6 GHz, 32 GB RAM). Table 10 shows the parameters and the initial values for the growth simulations which were derived from experimental cultivation studies.

Figure 14 shows the measured values and simulated timelines for the cell density (a, c), as well as the substrate and metabolites (b, d). The simulated timelines show

t10.1 **Table 10** Cell growth-dependent parameters used for the simulations of the MC-based hMSC cell growth in the SP100 and SP300

t10.2	Parameter	Values	Parameter	Values
t10.3	μ_{max}	1/d	Lac	mmol/L
t10.4	Amn	mmol/L	q_{Amn}	mmol/cell/d
t10.5	Glc	mmol/L	q_{Glc}	mmol/cell/d
t10.6	k_{at}	1/d	q_{Lac}	mmol/cell/d
t10.7	k_{det}	1/d	t_l	d
t10.8	K_{Amn}	mmol/L	X_A	cells/mL
t10.9	K_{Glc}	mmol/L	X_{Sus}	cells/mL
t10.10	K_{Lav}	mmol/L		




Fig. 14 Comparison of experimental (symbols) and simulated (line) data for cell density (a, c) and substrate/metabolites (b, d). The growth simulations were performed for the SP100 (a, b) and SP300 (c, d)

pleasing overall correlation with the values measured experimentally and demonstrate the applicability of the unstructured, segregated growth model. By using determined growth parameters from cultivation studies, the cell growth, glucose consumption, lactate production, and ammonium production could be proficiently approximated. The greatest deviations in cell density were in the range of 3–20% for the cells in suspension and 4–24% for the cells on the MCs. The glucose, lactate, and ammonium timelines also correspond to this pattern, even though the specific substrate consumption and metabolite production rates were prone to errors. However, the models provide reliable predictions for the MC-based hMSC growth in the two spinner flask types.

5 Conclusions and Outlook

In this review, the current state of the art of the in vitro expansion of hMSC and the use of numerical tools to support the development of MC-based hMSCs expansions as well as the establishment of “Digital Twins” have been presented. It has been emphasized that different CFD model approaches are described in the scientific literature which can be successfully applied for the characterization of SU bioreactors, especially for the process development of hMSC expansion processes. The CFD case study presented clearly demonstrates that numerical models are valuable tools for the biochemical engineering characterization of small-scale spinner flasks, especially for the determination of parameters that are difficult to determine experimentally. A good correlation was always found between the parameters predicted by the CFD and those measured experimentally. This observation was also in agreement with the literature data. The *Euler-Euler* and *Euler-Lagrange* models gave adequate predictions of the MC distributions within the spinner flask systems and were correlated qualitatively with experimental observations. The *Euler-Lagrange* approach allowed the calculation of particle histories due to its discrete particle formulation, which can be combined with experimental cultivation studies. Thus, *Euler-Lagrange* modelling should be favored in the future in order to derive hydrodynamic stresses over time instead of volume-weighted data. The scientific literature summarized also shows that different model approaches for the simulation of the hMSC growth are available, even though only a few are applicable for the MC-based growth simulation in a stirred bioreactor. The unstructured and segregated growth model presented gives a good description of the MC-based hMSC expansion process in the two spinner flask systems. Thus, MC-based hMSC cell growth can be predicted. However, the further development of descriptive, or even predictive, models for hMSCs will be important in the future for exact scheduling of the preparation of the cell material and the subsequent autologous therapy.

915 **References**

- 916 1. Grand View Research (2020) Cell therapy market size, share and trends analysis report,
917 2020–2027
- 918 2. Malik NN, Durdy MB (2015) Cell therapy landscape. In: Translational regenerative medicine.
919 Elsevier, pp 87–106
- 920 3. Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K, Vanek P, Farid SS (2014)
921 Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion
922 technologies. *Biotechnol Bioeng* 111:69–83. <https://doi.org/10.1002/bit.25008>
- 923 4. Sharma S, Raju R, Sui S, Hu W-S (2011) Stem cell culture engineering – process scale up and
924 beyond. *Biotechnol J* 6:1317–1329. <https://doi.org/10.1002/biot.201000435>
- 925 5. Ren G, Chen X, Dong F, Li W (2012) Concise review: mesenchymal stem cells and
926 translational medicine: emerging issues. *Stem Cells Transl Med* 1:51–58
- 927 6. Capelli C, Pedrini O, Valgardsdottir R, Da Roit F, Golay J, Introna M (2015) Clinical grade
928 expansion of MSCs. *Immunol Lett* 168:222–227. <https://doi.org/10.1016/j.imlet.2015.06.006>
- 929 7. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S,
930 Eckstein V, Ho AD (2008) Replicative senescence of mesenchymal stem cells: a continuous
931 and organized process. *PLoS One* 3:e2213. <https://doi.org/10.1371/journal.pone.0002213>
- 932 8. Lo Surdo J, Bauer SR (2012) Quantitative approaches to detect donor and passage differences
933 in adipogenic potential and clonogenicity in human bone marrow-derived mesenchymal stem
934 cells. *Tissue Eng Part C Methods* 18:877–889. <https://doi.org/10.1089/ten.tec.2011.0736>
- 935 9. Heathman TRJ, Rafiq QA, Chan AKC, Coopman K, Nienow AW, Kara B, Hewitt CJ (2016)
936 Characterization of human mesenchymal stem cells from multiple donors and the implications
937 for large scale bioprocess development. *Biochem Eng J* 108:14–23. <https://doi.org/10.1016/j.bej.2015.06.018>
- 939 10. Das R, Roosloot R, van Pel M, Schepers K, Driessen M, Fibbe WE, de Bruijn JD, Roelofs H
940 (2019) Preparing for cell culture scale-out: establishing parity of bioreactor- and flask-
941 expanded mesenchymal stromal cell cultures. *J Transl Med* 17:241. <https://doi.org/10.1186/s12967-019-1989-x>
- 943 11. Jossen V, Schirmer C, Mostafa Sindi D, Eibl R, Kraume M, Pörtner R, Eibl D (2016)
944 Theoretical and practical issues that are relevant when scaling up hMSC microcarrier produc-
945 tion processes. *Stem Cells Int* 2016:1–15. <https://doi.org/10.1155/2016/4760414>
- 946 12. Jossen V, Eibl R, Kraume M, Eibl D (2018) Growth behavior of human adipose tissue-derived
947 stromal/stem cells at small scale: numerical and experimental investigations. *Bioengineering*
948 5:106. <https://doi.org/10.3390/bioengineering5040106>
- 949 13. Hassan S, Simaria AS, Varadaraju H, Gupta S, Warren K, Farid SS (2015) Allogeneic cell
950 therapy bioprocess economics and optimization: downstream processing decisions. *Regen*
951 *Med* 10:591–609
- 952 14. Lipsitz YY, Milligan WD, Fitzpatrick I, Stalmeijer E, Farid SS, Tan KY, Smith D, Perry R,
953 Carmen J, Chen A, Mooney C, Fink J (2017) A roadmap for cost-of-goods planning to guide
954 economic production of cell therapy products. *Cytotherapy* 19:1383–1391. <https://doi.org/10.1016/j.jcyt.2017.06.009>
- 956 15. García-Fernández C, López-Fernández A, Borrós S, Lecina M, Vives J (2020) Strategies for
957 large-scale expansion of clinical-grade human multipotent mesenchymal stromal cells.
958 *Biochem Eng J* 159:107601. <https://doi.org/10.1016/j.bej.2020.107601>
- 959 16. Dolley-Sonneville P, Melkounian Z, Romeo L. Corning® Stemgro® hMSC Medium. Corning
960 Appl Note 1–8
- 961 17. Gottipamula S, Muttigi MS, Chaansa S, Ashwin KM, Priya N, Kolkundkar U, Sundar Raj S,
962 Sen MA, Seetharam RN (2016) Large-scale expansion of pre-isolated bone marrow mesen-
963 chymal stromal cells in serum-free conditions. *J Tissue Eng Regen Med* 10:108–119. <https://doi.org/10.1002/term.1713>
- 964

18. Carter SM, Granchelli J, Stelzer T (2014) Large scale expansion and differentiation of human mesenchymal stromal cells in the Thermo Scientific nunc cell factory system. *Thermo Sci Appl Note* 1:1–6 965
19. Jossen V, Muoio F, Panella S, Harder Y, Tallone T, Eibl R (2020) An approach towards a GMP compliant in-vitro expansion of human adipose stem cells for autologous therapies. *Bioengineering in submit* 968
20. Reichardt A, Polchow B, Shakibaei M, Henrich W, Hetzer R, Lueders C (2013) Large scale expansion of human umbilical cord cells in a rotating bed system bioreactor for cardiovascular tissue engineering applications. *Open Biomed Eng J* 7:50–61. <https://doi.org/10.2174/1874120701307010050> 970 AUS
21. Ikebe C, Suzuki K (2014) Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. *Biomed Res Int* 2014:1–11. <https://doi.org/10.1155/2014/951512> 975
22. Scibona E, Morbidelli M (2019) Expansion processes for cell-based therapies. *Biotechnol Adv* 37:107455. <https://doi.org/10.1016/j.biotechadv.2019.107455> 976
23. Discher DE, Mooney DJ, Zandstra PW (2010) Growth factors, matrices, and forces combine. *Growth (Lakeland)* 324:1673–1677. <https://doi.org/10.1126/science.1171643.Growth> 977
24. Steward AJ, Kelly DJ (2015) Mechanical regulation of mesenchymal stem cell differentiation. *J Anat* 227:717–731. <https://doi.org/10.1111/joa.12243> 978
25. Kaiser SC, Eibl D, Eibl R (2015) Single-use bioreactors for animal and human cells. In: *Animal cell culture: cell engineering*. Springer, Cham, pp 445–499 983
26. Baraniak PR, McDevitt TC (2012) Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves multilineage potential. *Cell Tissue Res* 347:701–711. <https://doi.org/10.1007/s00441-011-1215-5> 984
27. Frith JE, Thomson B, Genever PG (2010) Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. *Tissue Eng Part C Methods* 16:735–749. <https://doi.org/10.1089/ten.tec.2009.0432> 985
28. Alimperti S, Lei P, Wen Y, Tian J, Campbell AM, Andreadis ST (2014) Serum-free spheroid suspension culture maintains mesenchymal stem cell proliferation and differentiation potential. *Biotechnol Prog* 30:974–983. <https://doi.org/10.1002/btpr.1904> 986
29. Allen LM, Matyas J, Ungrin M, Hart DA, Sen A (2019) Serum-free culture of human mesenchymal stem cell aggregates in suspension bioreactors for tissue engineering applications. *Stem Cells Int* 2019:1–18. <https://doi.org/10.1155/2019/4607461> 987
30. Bhang SH, Cho S-W, La W-G, Lee T-J, Yang HS, Sun A-Y, Baek S-H, Rhie J-W, Kim B-S (2011) Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells. *Biomaterials* 32:2734–2747. <https://doi.org/10.1016/j.biomaterials.2010.12.035> 988
31. Layer PG, Robitzki A, Rothermel A, Willbold E (2002) Of layers and spheres: the reaggregate approach in tissue engineering. *Trends Neurosci* 25:131–134. [https://doi.org/10.1016/S0166-2236\(00\)02036-1](https://doi.org/10.1016/S0166-2236(00)02036-1) 989
32. Achilli T-M, Meyer J, Morgan JR (2012) Advances in the formation, use and understanding of multi-cellular spheroids. *Expert Opin Biol Ther* 12:1347–1360. <https://doi.org/10.1517/14712598.2012.707181> 990
33. Page H, Flood P, Reynaud EG (2013) Three-dimensional tissue cultures: current trends and beyond. *Cell Tissue Res* 352:123–131. <https://doi.org/10.1007/s00441-012-1441-5> 991
34. Edmondson R, Broglie JJ, Adcock AF, Yang L (2014) Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. *Assay Drug Dev Technol* 12:207–218. <https://doi.org/10.1089/adt.2014.573> 992
35. Caron MMJ, Emans PJ, Coolsen MME, Voss L, Surtel DAM, Cremers A, van Rhijn LW, Welting TJM (2012) Redifferentiation of dedifferentiated human articular chondrocytes: comparison of 2D and 3D cultures. *Osteoarthritis Cartil* 20:1170–1178. <https://doi.org/10.1016/j.joca.2012.06.016> 993
36. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM (2013) Stromal cells from the adipose tissue-derived stromal 994

- 1018 vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint
1019 statement of the International Federation for Adipose Therapeutics and Science (IFATS) and
1020 the International So. Cytotherapy 15:641–648. <https://doi.org/10.1016/j.jcyt.2013.02.006>
- 1021 37. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R,
1022 Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesen-
1023 chymal stromal cells. The International Society for Cellular Therapy position statement.
1024 Cytotherapy 8:315–317. <https://doi.org/10.1080/14653240600855905>
- 1025 38. Cheng N-C, Chen S-Y, Li J-R, Young T-H (2013) Short-term spheroid formation enhances the
1026 regenerative capacity of adipose-derived stem cells by promoting stemness, angiogenesis, and
1027 chemotaxis. Stem Cells Transl Med 2:584–594. <https://doi.org/10.5966/sctm.2013-0007>
- 1028 39. Bartosh TJ, Ylostalo JH, Mohammadipour A, Bazhanov N, Coble K, Claypool K, Lee RH,
1029 Choi H, Prockop DJ (2010) Aggregation of human mesenchymal stromal cells (MSCs) into
1030 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci
1031 107:13724–13729. <https://doi.org/10.1073/pnas.1008117107>
- 1032 40. YiÖstalo JH, Bartosh TJ, Coble K, Prockop DJ (2012) Human mesenchymal stem/stromal
1033 cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimu-
1034 lated macrophages into an anti-inflammatory phenotype. Stem Cells 30:2283–2296. <https://doi.org/10.1002/stem.1191>
- 1035 41. Zimmermann JA, Mcdevitt TC (2014) Pre-conditioning mesenchymal stromal cell spheroids
1036 for immunomodulatory paracrine factor secretion. Cytotherapy 16:331–345. <https://doi.org/10.1016/j.jcyt.2013.09.004>
- 1037 42. Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, Koch C, Drescher W,
1038 Hutschenreuther G, Zenke M, Ho AD, Wagner W (2010) Impact of individual platelet lysates
1039 on isolation and growth of human mesenchymal stromal cells. Cytotherapy 12:888–898.
1040 <https://doi.org/10.3109/14653249.2010.501788>
- 1041 43. Badenes SM, Fernandes TG, Rodrigues CAV, Diogo MM, Cabral JMS (2016) Microcarrier-
1042 based platforms for in vitro expansion and differentiation of human pluripotent stem cells in
1043 bioreactor culture systems. J Biotechnol 234:71–82. <https://doi.org/10.1016/j.jbiotec.2016.07.023>
- 1044 44. Villa-Diaz LG, Ross AM, Lahann J, Krebsbach PH (2013) Concise review: the evolution of
1045 human pluripotent stem cell culture: from feeder cells to synthetic coatings. Stem Cells 31:1–7.
1046 <https://doi.org/10.1002/stem.1260>
- 1047 45. Shearier E, Xing Q, Qian Z, Zhao F (2016) Physiologically low oxygen enhances biomolecule
1048 production and stemness of mesenchymal stem cell spheroids. Tissue Eng Part C Methods
1049 22:360–369. <https://doi.org/10.1089/ten.tec.2015.0465>
- 1050 46. Wu J, Rostami MR, Cadavid Olaya DP, Tzanakakis ES (2014) Oxygen transport and stem cell
1051 aggregation in stirred-suspension bioreactor cultures. PLoS One 9:e102486. <https://doi.org/10.1371/journal.pone.0102486>
- 1052 47. Lei Y, Schaffer DV (2013) A fully defined and scalable 3D culture system for human
1053 pluripotent stem cell expansion and differentiation. Proc Natl Acad Sci 110:E5039–E5048.
1054 <https://doi.org/10.1073/pnas.1309408110>
- 1055 48. Sart S, Tsai A-C, Li Y, Ma T (2014) Three-dimensional aggregates of mesenchymal stem
1056 cells: cellular mechanisms, biological properties, and applications. Tissue Eng Part B Rev
1057 20:365–380. <https://doi.org/10.1089/ten.teb.2013.0537>
- 1058 49. Sucusky P, Osorio DF, Brown JB, Neitzel GP (2004) Fluid mechanics of a spinner-flask
1059 bioreactor. Biotechnol Bioeng 85:34–46. <https://doi.org/10.1002/bit.10788>
- 1060 50. Kaiser S, Jossen V, Schirmaier C, Eibl D, Brill S, van den Bos C, Eibl R (2013) Fluid flow and
1061 cell proliferation of mesenchymal adipose-derived stem cells in small-scale, stirred, single-use
1062 bioreactors. Chem Ing Tech 85:95–102. <https://doi.org/10.1002/cite.201200180>
- 1063 51. vn Wezel AL (1967) Growth of cell-strains and primary cells on microcarriers in homoge-
1064 neous culture. Nature 216:64–65

52. Chen AK-L, Reuveny S, Oh SKW (2013) Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction. *Biotechnol Adv* 31:1032–1046. <https://doi.org/10.1016/j.biotechadv.2013.03.006>
53. Jossen V, van den Bos C, Eibl R, Eibl D (2018) Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. *Appl Microbiol Biotechnol* 102:3981–3994. <https://doi.org/10.1007/s00253-018-8912-x>
54. Rafiq QA, Ruck S, Hanga MP, Heathman TRJ, Coopman K, Nienow AW, Williams DJ, Hewitt CJ (2018) Qualitative and quantitative demonstration of bead-to-bead transfer with bone marrow-derived human mesenchymal stem cells on microcarriers: utilising the phenomenon to improve culture performance. *Biochem Eng J* 135:11–21. <https://doi.org/10.1016/j.bej.2017.11.005>
55. Leber J, Barezkai J, Blumenstock M, Pospisil B, Salzig D, Czermak P (2017) Microcarrier choice and bead-to-bead transfer for human mesenchymal stem cells in serum-containing and chemically defined media. *Process Biochem* 59:255–265. <https://doi.org/10.1016/j.procbio.2017.03.017>
56. Szczypka M, Splan D, Woolls H, Brandwein H (2014) Single-use bioreactors and microcarriers. *Bioprocess Int* 12:54–64
57. Zhao L-G, Chen S-L, Teng Y-J, An L-P, Wang J, Ma J-L, Xia Y-Y (2014) The MEK5/ERK5 pathway mediates fluid shear stress promoted osteoblast differentiation. *Connect Tissue Res* 55:96–102. <https://doi.org/10.3109/03008207.2013.853755>
58. Yim EK, Sheetz MP (2012) Force-dependent cell signaling in stem cell differentiation. *Stem Cell Res Ther* 3:41. <https://doi.org/10.1186/scrt132>
59. Frauenschuh S, Reichmann E, Ibold Y, Goetz PM, Sittlinger M, Ringe J (2007) A microcarrier-based cultivation system for expansion of primary mesenchymal stem cells. *Biotechnol Prog* 23:187–193. <https://doi.org/10.1021/bp060155w>
60. Panchalingam KM, Jung S, Rosenberg L, Behie LA (2015) Bioprocessing strategies for the large-scale production of human mesenchymal stem cells: a review. *Stem Cell Res Ther* 6:225. <https://doi.org/10.1186/s13287-015-0228-5>
61. Ferrari C, Balandras F, Guedon E, Olmos E, Chevalot I, Marc A (2012) Limiting cell aggregation during mesenchymal stem cell expansion on microcarriers. *Biotechnol Prog* 28:780–787. <https://doi.org/10.1002/btpr.1527>
62. Schirmaier C, Jossen V, Kaiser SC, Jüngerkes F, Brill S, Safavi-Nab A, Siehoff A, van den Bos C, Eibl D, Eibl R (2014) Scale-up of adipose tissue-derived mesenchymal stem cell production in stirred single-use bioreactors under low-serum conditions. *Eng Life Sci* 14:292–303. <https://doi.org/10.1002/elsc.201300134>
63. Lawson T, Kehoe DE, Schnitzler AC, Rapijko PJ, Der KA, Philbrick K, Punreddy S, Rigby S, Smith R, Feng Q, Murrell JR, Rook MS (2017) Process development for expansion of human mesenchymal stromal cells in a 50L single-use stirred tank bioreactor. *Biochem Eng J* 120:49–62. <https://doi.org/10.1016/j.bej.2016.11.020>
64. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer AB (2004) Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cell under in vitro conditions. *Platelets* 15:29–35
65. Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR (2007) Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. *J Cell Physiol* 213:18–26
66. Abdelrazik H, Spaggiari GM, Chiossone L, Mretta L (2011) Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. *Eur J Immunol* 41:3281–3290
67. Heathman TRJJ, Glyn VAM, Picken A, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt CJ (2015) Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process. *Biotechnol Bioeng* 112:1696–1707. <https://doi.org/10.1002/bit.25582>

- 1122 68. Carmelo JG, Fernandes-Platzgummer A, Diogo MM, da Silva CL, Cabral JMS (2015) A xeno-
1123 free microcarrier-based stirred culture system for the scalable expansion of human mesenchy-
1124 mal stem/stromal cells isolated from bone marrow and adipose tissue. *Biotechnol J*
1125 10:1235–1247. <https://doi.org/10.1002/biot.201400586>
- 1126 69. Rafiq QA, Coopman K, Nienow AW, Hewitt CJ (2016) Systematic microcarrier screening and
1127 agitated culture conditions improves human mesenchymal stem cell yield in bioreactors.
1128 *Biotechnol J* 11:473–486. <https://doi.org/10.1002/biot.201400862>
- 1129 70. Heathman TRJ, Stolzing A, Fabian C, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt
1130 CJ (2016) Scalability and process transfer of mesenchymal stromal cell production from
1131 monolayer to microcarrier culture using human platelet lysate. *Cytotherapy* 18:523–535.
1132 <https://doi.org/10.1016/j.jcyt.2016.01.007>
- 1133 71. Nienow AW, Hewitt CJ, Heathman TRJ, Glyn VAM, Fonte GN, Hanga MP, Coopman K,
1134 Rafiq QA (2016) Agitation conditions for the culture and detachment of hMSCs from
1135 microcarriers in multiple bioreactor platforms. *Biochem Eng J* 108:24–29. <https://doi.org/10.1016/j.bej.2015.08.003>
- 1137 72. Dufey V, Tachenay A, Art M, Becken U, De Longueville F (2016) Expansion of human bone
1138 marrow-derived mesenchymal stem cells in BioBLU 0.3c single-use bioreactors. *Appl Note*
1139 305:1–8
- 1140 73. Heathman TRJ, Nienow AW, Rafiq QA, Coopman K, Bo K, Hewitt CJ (2019) Development
1141 of a process control strategy for the serum-free microcarrier expansion of human mesenchymal
1142 stem cells towards cost-effective and commercially viable manufacturing. *Biochem Eng J*
1143 141:200–209. <https://doi.org/10.1016/j.bej.2018.10.018>
- 1144 74. Jossen V, Kaiser SC, Schirmaier C, Herrmann J, Tappe A, Eibl D, Siehoff A, van d BC, Eibl R
1145 (2014) Modification and qualification of a stirred single-use bioreactor for the improved
1146 expansion of human mesenchymal stem cells at benchtop scale. *Pharm Bioprocess*
1147 2:311–322. <https://doi.org/10.4155/pbp.14.29>
- 1148 75. Jossen V, Pörtner R, Kaiser SC, Kraume M, Eibl D, Eibl R (2014) Mass production of
1149 mesenchymal stem cells – impact of bioreactor design and flow conditions on proliferation
1150 and differentiation. In: Eberli D (ed) *Cells and biomaterials in regenerative medicine*. InTech,
1151 Rijeka, pp 119–174
- 1152 76. Siddiquee K, Sha M (2014) Large-scale production of human mesenchymal stem cells in
1153 BioBLU 5c single-use vessels
- 1154 77. Bery JD, Liovic P, Šutalo ID, Stewart RL, Glattauer V, Meagher L (2016) Characterisation of
1155 stresses on microcarriers in a stirred bioreactor. *App Math Model* 40:6787–6804. <https://doi.org/10.1016/j.apm.2016.02.025>
- 1157 78. Paschedag AR (2004) *CFD in der Vevfahrenstechnik*. Wiley-VCH Verlag GmbH & Co.
- 1158 79. Ferziger JH, Peric M, Leonard A (1997) Computational methods for fluid dynamics. *Phys*
1159 *Today* 50:80–84. <https://doi.org/10.1063/1.881751>
- 1160 80. Rodriguez S (2019) *Applied computational fluid dynamics and turbulence modeling*. Springer
1161 International Publishing, Cham
- 1162 81. Delafosse A, Collignon M-L, Marc A, Toye D, Olmos E (2015) Revisiting the determination
1163 of hydromechanical stresses encountered by microcarriers in stem cell culture bioreactors.
1164 *BMC Proc* 9:P41. <https://doi.org/10.1186/1753-6561-9-S9-P41>
- 1165 82. Liovic P, Šutalo ID, Stewart R, Glattauer V, Meagher L (2012) Fluid flow and stresses on
1166 microcarriers in spinner flask bioreactors. *Ninth Int Conf CFD Miner Process Ind*:1–6
- 1167 83. Delafosse A, Calvo S, Collignon M-L, Delvigne F, Crine M, Toye D (2015) Euler–Lagrange
1168 approach to model heterogeneities in stirred tank bioreactors – comparison to experimental
1169 flow characterization and particle tracking. *Chem Eng Sci* 134:457–466. <https://doi.org/10.1016/j.ces.2015.05.045>
- 1170 84. Nienow AW, Rielly CD, Brosnan K, Bargh N, Lee K, Coopman K, Hewitt CJ (2013) The
1172 physical characterisation of a microscale parallel bioreactor platform with an industrial CHO
1173 cell line expressing an IgG4. *Biochem Eng J* 76:25–36. <https://doi.org/10.1016/j.bej.2013.04.011>
- 1174 011

85. Collignon M-L, Delafosse A, Calvo S, Martin C, Marc A, Toye D, Olmos E (2016) Large- 1175
Eddy simulations of microcarrier exposure to potentially damaging eddies inside mini- 1176
bioreactors. *Biochem Eng J* 108:30–43. <https://doi.org/10.1016/j.bej.2015.10.020> 1177
86. Kunas KT, Papoutsakis ET (1990) The protective effect of serum against hydrodynamic 1178
damage of hybridoma cells in agitated and surface-aerated bioreactors. *J Biotechnol* 1179
15:57–69. [https://doi.org/10.1016/0168-1656\(90\)90051-C](https://doi.org/10.1016/0168-1656(90)90051-C) 1180
87. Michaels JD, Petersen JF, McIntire LV, Papoutsakis ET (1991) Protection mechanisms of 1181
freely suspended animal cells (CRL 8018) from fluid-mechanical injury. Viscometric and 1182
bioreactor studies using serum, pluronic F68 and polyethylene glycol. *Biotechnol Bioeng* 1183
38:169–180. <https://doi.org/10.1002/bit.260380209> 1184
88. Chisti Y (2000) Animal-cell damage in sparged bioreactors. *Trends Biotechnol* 18:420–432. 1185
[https://doi.org/10.1016/S0167-7799\(00\)01474-8](https://doi.org/10.1016/S0167-7799(00)01474-8) 1186
89. Jossen V (2020) Bioengineering aspects of microcarrier-based hMSC expansions in different 1187
single-use bioreactors. Technical University of Berlin, Berlin 1188
90. Stoots CM, Calabrese RV (1995) Mean velocity field to a rushton turbine blade. *Am Inst* 1189
Chem Eng J 41:1–11 1190
91. Wollny S (2010) Experimentelle und numerische Untersuchungen zur Partikelbeanspruchung 1191
in gerührten (Bio-)Reaktoren. Technical University of Berlin 1192
92. Venkat RV, Stock LR, Chalmers JJ (2000) Study of hydrodynamics in microcarrier culture 1193
spinner vessels: a particle tracking velocimetry approach. *Biotechnol Bioeng* 49:456–466. 1194
[https://doi.org/10.1002/\(SICI\)1097-0290\(19960220\)49:4<456::AID-BIT13>3.0.CO;2-8](https://doi.org/10.1002/(SICI)1097-0290(19960220)49:4<456::AID-BIT13>3.0.CO;2-8) 1195
93. Ismadi M-Z, Hourigan K, Fouras A (2014) Experimental characterisation of fluid mechanics in 1196
a spinner flask bioreactor. *Processes* 2:753–772. <https://doi.org/10.3390/pr2040753> 1197
94. Zhang H, Lamping SR, Pickering SCR, Lye GJ, Shamlou PA (2008) Engineering character- 1198
istics of a single well from 24-well and 96-well microtitre plates. *Biochem Eng J* 40:138–149 1199
95. Godara P, McFarland CD, Nordon RE (2008) Design of bioreactors for mesenchymal stem 1200
cell tissue engineering. *J Chem Technol Biotechnol* 83:408–420. <https://doi.org/10.1002/jctb.1918> 1201
96. Rafiq QA, Brosnan KM, Coopman K, Nienow AW, Hewitt CJ (2013) Culture of human 1203
mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. *Biotechnol Lett* 1204
35:1233–1245. <https://doi.org/10.1007/s10529-013-1211-9> 1205
97. Ibrahim S, Nienow AW (2004) Suspension of microcarriers for cell culture with axial flow 1206
impellers. *Chem Eng Res Des* 82:1082–1088. <https://doi.org/10.1205/cerd.82.9.1082.44161> 1207
98. Hewitt CJ, Lee K, Nienow AW, Thomas RJ, Smith M, Thomas CR (2011) Expansion of 1208
human mesenchymal stem cells on microcarriers. *Biotechnol Lett* 33:2325–2335. <https://doi.org/10.1007/s10529-011-0695-4> 1209
99. Yourek G, McCormick SM, Mao JJ, Reilly GC (2010) Shear stress induces osteogenic 1211
differentiation of human mesenchymal stem cells. *Regen Med* 5:713–724. <https://doi.org/10.2217/rme.10.60> 1212
100. Yourek G, Hussain MA, Mao JJ (2007) Cytoskeletal changes of mesenchymal stem cells 1214
during differentiation. *ASAIO J* 53:219–228. <https://doi.org/10.1097/MAT.0b013e31802deb2d> 1215
101. Yeatts AB, Choquette DT, Fisher JP (2013) Bioreactors to influence stem cell fate: augmen- 1217
tation of mesenchymal stem cell signaling pathways via dynamic culture systems. *Biochim* 1218
Biophys Acta Gen Subj 1830:2470–2480. <https://doi.org/10.1016/j.bbagen.2012.06.007> 1219
102. Yeatts AB, Fisher JP (2011) Bone tissue engineering bioreactors: dynamic culture and the 1220
influence of shear stress. *Bone* 48:171–181. <https://doi.org/10.1016/j.bone.2010.09.138> 1221
103. Weyand B, Reimers K, Vogt PM (2011) Influences of extracellular matrix properties and flow 1222
shear stresses on stem cell shape in a three-dimensional dynamic environment. *IFMBE Proc* 1223
30:47–50 1224
104. Weyand B, Kasper C, Israelowitz M, Gille C, von Schroeder HP, Reimers K, Vogt PM (2012) 1225
A differential pressure laminar flow reactor supports osteogenic differentiation and 1226

- 1227 extracellular matrix formation from adipose mesenchymal stem cells in a macroporous
1228 ceramic scaffold. *Biores Open Access* 1:145–157
- 1229 105. Weyand B, Israelowitz M, von Schroeder HP, Vogt PM (2009) Fluid dynamics in bioreactor
1230 considerations for the theoretical and practical approach. *Adv Biochem Eng*
1231 *Biotechnol* 112:251–268
- 1232 106. Croughan MS, Hamel J-F, Wang DIC (2006) Hydrodynamic effects on animal cells grown in
1233 microcarrier cultures. *Biotechnol Bioeng* 95:295–305. <https://doi.org/10.1002/bit.21158>
- 1234 107. Heathman TRJ, Stolzing A, Fabian C, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt
1235 CJ (2015) Serum-free process development: improving the yield and consistency of human
1236 mesenchymal stromal cell production. *Cytotherapy* 17:1524–1535. <https://doi.org/10.1016/j.jcyt.2015.08.002>
- 1238 108. Cierpka K, Elseberg CL, Niss K, Kassem M, Salzig D, Czermak P (2013) hMSC production in
1239 disposable bioreactors with regards to GMP and PAT. *Chem Ing Tech* 85:67–75. <https://doi.org/10.1002/cite.201200151>
- 1240
- 1241 109. Rafiq QA, Hanga MP, Heathman TRJ, Coopman K, Nienow AW, Williams DJ, Hewitt CJ
1242 (2017) Process development of human multipotent stromal cell microcarrier culture using an
1243 automated high-throughput microbioreactor. *Biotechnol Bioeng* 114:2253–2266. <https://doi.org/10.1002/bit.26359>
- 1244
- 1245 110. Higuera G, Schop D, Janssen F, van Dijkhuizen-Radersma R, van Boxtel T, van Blitterswijk
1246 CA (2009) Quantifying in vitro growth and metabolism kinetics of human mesenchymal stem
1247 cells using a mathematical model. *Tissue Eng Part A* 15:2653–2663. <https://doi.org/10.1089/ten.tea.2008.0328>
- 1248
- 1249 111. dos Santos F, Andrade PZ, Boura JS, Abecasis MM, da Silva CL, Cabral JMS (2009) Ex vivo
1250 expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and
1251 metabolism under hypoxia. *J Cell Physiol* 223:n/a–n/a. <https://doi.org/10.1002/jcp.21987>
- 1252 112. Bartolini E, Manoli H, Costamagna E, Jeyaseelan HA, Hamad M, Irhimeh MR,
1253 Khademhosseini A, Abbas A (2015) Population balance modelling of stem cell culture in
1254 3D suspension bioreactors. *Chem Eng Res Des* 101:125–134. <https://doi.org/10.1016/j.cherd.2015.07.014>
- 1255
- 1256 113. Mancuso L, Ilaria Liuzzo M, Fadda S, Cincotti A, Pisu M, Concas A, Cao G (2010)
1257 Experimental analysis and modeling of bone marrow mesenchymal stem cells proliferation.
1258 *Chem Eng Sci* 65:562–568. <https://doi.org/10.1016/j.ces.2009.06.034>
- 1259 114. Bailón-Plaza A, van der Meulen MCH (2001) A mathematical framework to study the effects
1260 of growth factor influences on fracture healing. *J Theor Biol* 212:191–209. <https://doi.org/10.1006/jtbi.2001.2372>
- 1261
- 1262 115. Geris L, Peiffer V, Demol J, Oosterwyck H Van (2006) Modelling of in vitro mesenchymal
1263 stem cell cultivation, chondrogenesis and osteogenesis. *J Biomech* 41:466–466
- 1264 116. Schellenberg A, Stiehl T, Horn P, Joussen S, Pallua N, Ho AD, Wagner W (2012) Population
1265 dynamics of mesenchymal stromal cells during culture expansion. *Cytotherapy* 14:401–411.
1266 <https://doi.org/10.3109/14653249.2011.640669>
- 1267 117. Cholewa D, Stiehl T, Schellenberg A, Bokermann G, Joussen S, Koch C, Walenda T,
1268 Pallua N, Marciniak-Czochra A, Suschek CV, Wagner W (2011) Expansion of adipose
1269 mesenchymal stromal cells is affected by human platelet lysate and plating density. *Cell*
1270 *Transplant* 20:1409–1422. <https://doi.org/10.3727/096368910X557218>
- 1271 118. Hoffmann M, Kuska J-P, Zscharnack M, Loeffler M, Galle J (2011) Spatial organization of
1272 mesenchymal stem cells in vitro – results from a new individual cell-based model with podia.
PLoS One 6:e21960. <https://doi.org/10.1371/journal.pone.0021960>

Author Queries

Chapter No.:

Query Refs.	Details Required	Author's response
AU1	Please check whether the presentation of "Abbreviations" is appropriate.	
AU2	Note that some part of the text seems to be blurred in the artwork of Figs. 1 and 3. Please provide revised figures with better quality.	
AU3	Please check if "scale-up" is okay as edited.	
AU4	Text size is less than 5 pts in the artwork of Figs. 12 and 13. Please provide revised figures with better quality.	
AU5	Please provide complete bibliographic details for Ref. [19].	